{"protocolSection": {"identificationModule": {"nctId": "NCT01013753", "orgStudyIdInfo": {"id": "1222.27"}, "secondaryIdInfos": [{"id": "2009-013395-48", "type": "EUDRACT_NUMBER", "domain": "EudraCT"}], "organization": {"fullName": "Boehringer Ingelheim", "class": "INDUSTRY"}, "briefTitle": "A Study of the Safety and Efficacy of 4 Doses of BI 1744 CL Delivered Via the Respimat in Patients With Asthma.", "officialTitle": "A Randomised, Double-Blind, Placebo- and Active-Controlled, Incomplete Crossover Efficacy and Safety Comparison of 4-week Treatment Periods of Once Daily Treatment of 4 Doses of BI 1744 CL Inhalation Solution Delivered by the Respimat\u00ae in Patients With Asthma"}, "statusModule": {"statusVerifiedDate": "2014-05", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2010-02"}, "primaryCompletionDateStruct": {"date": "2011-01", "type": "ACTUAL"}, "completionDateStruct": {"date": "2011-01", "type": "ACTUAL"}, "studyFirstSubmitDate": "2009-11-13", "studyFirstSubmitQcDate": "2009-11-13", "studyFirstPostDateStruct": {"date": "2009-11-16", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2014-03-28", "resultsFirstSubmitQcDate": "2014-05-29", "resultsFirstPostDateStruct": {"date": "2014-06-05", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2014-06-17", "lastUpdatePostDateStruct": {"date": "2014-06-27", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Boehringer Ingelheim", "class": "INDUSTRY"}}, "descriptionModule": {"briefSummary": "The primary objective of this study is to determine the efficacy and safety of 4 doses of BI 1744 CL inhalation solution delivered by the Respimat\u00ae inhaler once daily for four weeks in patients with asthma in comparison to placebo."}, "conditionsModule": {"conditions": ["Asthma"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "CROSSOVER", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE"}}, "enrollmentInfo": {"count": 198, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Olodaterol (BI 1744) low", "type": "EXPERIMENTAL", "description": "Low dose inhaled orally once daily from the Respimat inhaler", "interventionNames": ["Drug: Olodaterol (BI 1744) low"]}, {"label": "Olodaterol (BI 1744) very low", "type": "EXPERIMENTAL", "description": "Very low dose inhaled orally once daily from the Respimat inhaler", "interventionNames": ["Drug: Olodaterol (BI 1744) very low"]}, {"label": "Olodaterol (BI 1744) medium", "type": "EXPERIMENTAL", "description": "Medium dose inhaled orally once daily from the Respimat inhaler", "interventionNames": ["Drug: Olodaterol (BI 1744) medium"]}, {"label": "Olodaterol (BI 1744) high", "type": "EXPERIMENTAL", "description": "High dose inhaled orally once daily from the Respimat inhaler", "interventionNames": ["Drug: Olodaterol (BI 1744) high"]}, {"label": "Formoterol 12 mcg", "type": "ACTIVE_COMPARATOR", "description": "12mcg inhaled twice daily from the Aerolizer inhaler", "interventionNames": ["Drug: Formoterol 12 mcg"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "Olodaterol (BI 1744) placebo inhaled once daily from the Respimat inhaler and/or Formoterol placebo inhaled twice daily from the Aerolizer inhaler", "interventionNames": ["Drug: Placebo"]}], "interventions": [{"type": "DRUG", "name": "Placebo", "description": "Determine efficacy and safety of Placebo inhaled once daily from the Respimat inhaler and/or twice daily from the Aerolizer inhaler", "armGroupLabels": ["Placebo"]}, {"type": "DRUG", "name": "Olodaterol (BI 1744) high", "description": "Determine efficacy and safety in 4 different doses of Olodaterol (BI 1744) inhaled once daily via the Respimat", "armGroupLabels": ["Olodaterol (BI 1744) high"]}, {"type": "DRUG", "name": "Olodaterol (BI 1744) medium", "description": "Determination of efficacy in 4 different doses of Olodaterol (BI 1744) inhaled once daily via the Respimat", "armGroupLabels": ["Olodaterol (BI 1744) medium"]}, {"type": "DRUG", "name": "Olodaterol (BI 1744) very low", "description": "Determination of efficacy in 4 different doses of Olodaterol (BI 1744) inhaled once daily via the Respimat", "armGroupLabels": ["Olodaterol (BI 1744) very low"]}, {"type": "DRUG", "name": "Formoterol 12 mcg", "description": "Determine efficacy and safety of 12 mcg Formoterol dose inhaled orally twice daily from the Aerolizer in comparison to other treatment groups", "armGroupLabels": ["Formoterol 12 mcg"]}, {"type": "DRUG", "name": "Olodaterol (BI 1744) low", "description": "Determine efficacy and safety of 4 different doses of Olodaterol (BI 1744) inhaled once daily via the Respimat", "armGroupLabels": ["Olodaterol (BI 1744) low"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Forced Expiratory Volume in 1 Second (FEV1) Area Under Curve 0-24 Hours (AUC 0-24h) Response at the End of Each Treatment Period", "description": "Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values at the randomisation visit. Means are adjusted for treatment, period, patient and study baseline. FEV1 AUC 0-24h was calculated from 0-24 hours post-dose using the trapezoidal rule, divided by the observation time (24h) to report in litres.", "timeFrame": "1 hour (h) prior and 10 minutes (min) prior to first dose (baseline) and -1 h, -10 mins, 30 min, 60 min, 2 h, 3 h, 4 h, 11 h 50 min, 12 h 30 min, 13 h, 14 h, 15 h, 16 h, 18 h, 20 h, 22 h, 23 h, and 23 h 50 min related to evening dose after 4 weeks"}], "secondaryOutcomes": [{"measure": "FEV1 Area Under Curve 0-12 h (AUC 0-12h) Response at the End of Each Treatment Period", "description": "Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values at the randomisation visit. Means are adjusted for treatment, period, patient and study baseline. FEV1 AUC 0-12h was calculated from 0-12 hours post-dose using the trapezoidal rule, divided by the observation time (12h) to report in litres.", "timeFrame": "1 hour (h) prior and 10 minutes (min) prior to first dose (baseline) and -1 h, -10 mins, 30 min, 60 min, 2 h, 3 h, 4 h, 11 h 50 min related to evening dose after 4 weeks"}, {"measure": "FEV1 Area Under Curve 12-24 h (AUC 12-24h) Response at the End of Each Treatment Period", "description": "Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values at the randomisation visit. Means are adjusted for treatment, period, patient and study baseline. FEV1 AUC 12-24h was calculated from 12-24 hours post-dose using the trapezoidal rule, divided by the observation time (12h) to report in litres.", "timeFrame": "1 hour (h) prior and 10 minutes (min) prior to first dose (baseline) and 11 h 50 min, 12 h 30 min, 13 h, 14 h, 15 h, 16 h, 18 h, 20 h, 22 h, 23 h, and 23 h 50 min related to evening dose after 4 weeks"}, {"measure": "Peak FEV1 Within 24 Hours Post-dose Response", "description": "Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values at the randomisation visit. Peak FEV1 within 24 hours post dose measured following the evening trial drug inhalation at the end of each 4 week period of randomised treatment. Means are adjusted for treatment, period, patient and study baseline.", "timeFrame": "1 hour (h) prior and 10 minutes (min) prior to first dose (baseline) and 30 min, 60 min, 2 h, 3 h, 4 h, 11 h 50 min, 12 h 30 min, 13 h, 14 h, 15 h, 16 h, 18 h, 20 h, 22 h, 23 h, and 23 h 50 min related to evening dose after 4 weeks"}, {"measure": "Trough FEV1 Response", "description": "Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values at the randomisation visit. Trough values were defined as the mean of 2 FEV1 values performed at the planned timepoints 23h and 23h 50min related to evening trial-drug inhalation at the end of each 4 week period of randomised treatment. Means are adjusted for treatment, period, patient and study baseline.", "timeFrame": "1 hour (h) prior and 10 minutes (min) prior to first dose (baseline) and 23 h, and 23 h 50 min related to evening dose after 4 weeks"}, {"measure": "Forced Vital Capacity (FVC) Area Under Curve 0-12 Hours (AUC 0-12h) Response", "description": "Response was defined as change from baseline. Study baseline FVC was defined as the mean of the available pre-dose FVC values at the randomisation visit. Means are adjusted for treatment, period, patient and study baseline. FVC AUC 0-12h was calculated using the trapezoidal rule, divided by the observation time to report in litres.", "timeFrame": "1 hour (h) prior and 10 minutes (min) prior to first dose (baseline) and -1 h, -10 mins, 30 min, 60 min, 2 h , 3 h, 4 h, 11 h 50 min related to evening dose after 4 weeks"}, {"measure": "FVC Area Under Curve 12-24 Hours (AUC 12-24h) Response", "description": "Response was defined as change from baseline. Study baseline FVC was defined as the mean of the available pre-dose FVC values at the randomisation visit. Means are adjusted for treatment, period, patient and study baseline. FVC AUC 12-24h was calculated using the trapezoidal rule, divided by the observation time to report in litres.", "timeFrame": "1 hour (h) prior and 10 minutes (min) prior to first dose (baseline) and 11 h 50 min, 12 h 30 min, 13 h, 14 h, 15 h, 16 h, 18 h, 20 h, 22 h, 23 h, and 23 h 50 min related to evening dose after 4 weeks"}, {"measure": "FVC Area Under Curve 0-24 Hours (AUC 0-24h) Response", "description": "Response was defined as change from baseline. Study baseline FVC was defined as the mean of the available pre-dose FVC values at the randomisation visit. Means are adjusted for treatment, period, patient and study baseline. FVC AUC 0-24h was calculated using the trapezoidal rule, divided by the observation time to report in litres.", "timeFrame": "1 hour (h) prior and 10 minutes (min) prior to first dose (baseline) and -1 h, -10 min, 30 min, 60 min, 2 h, 3 h, 4 h, 11 h 50 min, 12 h 30 min, 13 h, 14 h, 15 h, 16 h, 18 h, 20 h, 22 h, 23 h, and 23 h 50 min related to evening dose after 4 weeks"}, {"measure": "Peak FVC Within 24 Hours Post-dose Response", "description": "Response was defined as change from baseline. Study baseline FVC was defined as the mean of the available pre-dose FVC values at the randomisation visit. Peak FVC within 24 hours post dose measured following the trial drug inhalation at the end of each 4 week period of randomised treatment. Means are adjusted for treatment, period, patient and study baseline.", "timeFrame": "1 hour (h) prior and 10 minutes (min) prior to first dose (baseline) and 30 min, 60 min, 2 h, 3 h, 4 h, 11 h 50 min, 12 h 30 min, 13 h, 14 h, 15 h, 16 h, 18 h, 20 h, 22 h, 23 h, and 23 h 50 min related to evening dose after 4 weeks"}, {"measure": "Trough FVC Response", "description": "Response was defined as change from baseline. Study baseline FVC was defined as the mean of the available pre-dose FVC values at the randomisation visit. Trough values were defined as the mean of 2 FEV1 values performed at the planned timepoints 23h and 23h 50min related to evening trial-drug inhalation at the end of each 4 week period of randomised treatment. Means are adjusted for treatment, period, patient and study baseline.", "timeFrame": "1 hour (h) prior and 10 minutes (min) prior to first dose (baseline) and 23 h, and 23 h 50 min related to evening dose after 4 weeks"}, {"measure": "Peak Expiratory Flow (PEF) Area Under Curve 0-12 Hours (AUC 0-12h) Response", "description": "Response was defined as change from baseline. Study baseline PEF was defined as the mean of the available pre-dose PEF values at the randomisation visit. Means are adjusted for treatment, period, patient and study baseline. PEF AUC 0-12h was calculated using the trapezoidal rule, divided by the observation time to report in litres/seconds.", "timeFrame": "1 hour (h) prior and 10 minutes (min) prior to first dose (baseline) and -1 h, -10 mins, 30 min, 60 min, 2 h, 3 h, 4 h, 11 h 50 min related to evening dose after 4 weeks"}, {"measure": "PEF Area Under Curve 12-24 Hours (AUC 12-24h) Response", "description": "Response was defined as change from baseline. Study baseline PEF was defined as the mean of the available pre-dose PEF values at the randomisation visit. Means are adjusted for treatment, period, patient and study baseline. PEF AUC 12-24h was calculated using the trapezoidal rule, divided by the observation time to report in litres/seconds.", "timeFrame": "1 hour (h) prior and 10 minutes (min) prior to first dose (baseline) and 11 h 50 min, 12 h 30 min, 13 h, 14 h, 15 h, 16 h, 18 h, 20 h, 22 h, 23 h, and 23 h 50 min related to evening dose after 4 weeks"}, {"measure": "Peak Expiratory Flow (PEF) Area Under Curve 0-24 Hours (AUC 0-24h) Response", "description": "Response was defined as change from baseline. Study baseline PEF was defined as the mean of the available pre-dose PEF values at the randomisation visit. Means are adjusted for treatment, period, patient and study baseline. PEF AUC 0-24h was calculated using the trapezoidal rule, divided by the observation time to report in litres/seconds.", "timeFrame": "1 hour (h) prior and 10 minutes (min) prior to first dose (baseline) and -1h, -10 mins, 30 min, 60 min, 2 h, 3 h, 4 h, 11 h 50 min, 12 h 30 min, 13 h, 14 h, 15 h, 16 h, 18 h, 20 h, 22 h, 23 h, and 23 h 50 min related to evening dose after 4 weeks"}, {"measure": "Peak PEF Within 24 Hours Post-dose Response", "description": "Response was defined as change from baseline. Study baseline PEF was defined as the mean of the available pre-dose PEF values at the randomisation visit. Peak PEF within 24 hours post-dose measured following the evening trial drug inhalation at the end of each 4 week period of randomised treatment. Means are adjusted for treatment, period, patient and study baseline.", "timeFrame": "1 hour (h) prior and 10 minutes (min) prior to first dose (baseline) and 30 min, 60 min, 2 h, 3 h, 4 h, 11 h 50 min, 12 h 30 min, 13 h, 14 h, 15 h, 16 h, 18 h, 20 h, 22 h, 23 h, and 23 h 50 min related to evening dose after 4 weeks"}, {"measure": "Trough PEF Response", "description": "Response was defined as change from baseline. Study baseline PEF was defined as the mean of the available pre-dose PEF values at the randomisation visit. Trough values were defined as the mean of 2 FEV1 values performed at the planned timepoints 23h and 23h 50min related to evening trial-drug inhalation at the end of each 4 week period of randomised treatment. Means are adjusted for treatment, period, patient and study baseline.", "timeFrame": "1 hour (h) prior and 10 minutes (min) prior to first dose (baseline) and 23 h, and 23 h 50 min related to evening dose after 4 weeks"}, {"measure": "Mean Pre-dose Morning PEF (PEF a.m.)", "description": "PEF a.m. was measured by patients at home using the AM2+ device (overall means obtained during each period of randomised treatment excluding the data of the first 2 weeks will be compared). Means are adjusted for treatment, period, patient and study baseline.", "timeFrame": "2-4 weeks"}, {"measure": "Mean Pre-dose Evening PEF (PEF p.m.)", "description": "PEF p.m. was measured by patients at home using the AM2+ device (overall means obtained during each period of randomised treatment excluding the data of the first 2 weeks will be compared). Means are adjusted for treatment, period, patient and study baseline.", "timeFrame": "2-4 weeks"}, {"measure": "PEF Daily Variability", "description": "PEF daily variability was assessed by patients at home using the AM2+ device (overall means obtained during each period of randomised treatment excluding the data of the first 2 weeks will be compared). PEF daily variability is the absolute difference between the morning and the evening PEF value divided by the mean of these two values, expressed as a percent. Means are adjusted for treatment, period, patient and study baseline.", "timeFrame": "2-4 weeks"}, {"measure": "Mean Pre-dose Morning FEV1 (FEV1 a.m.)", "description": "FEV1 a.m. was measured by patients at home using the AM2+ device (overall means obtained during each period of randomised treatment excluding the data of the first 2 weeks will be compared). Means are adjusted for treatment, period, patient and study baseline.", "timeFrame": "2-4 weeks"}, {"measure": "Mean Pre-dose Evening FEV1 (FEV1 p.m.)", "description": "FEV1 p.m. was measured by patients at home using the AM2+ device (overall means obtained during each period of randomised treatment excluding the data of the first 2 weeks will be compared). Means are adjusted for treatment, period, patient and study baseline.", "timeFrame": "2-4 weeks"}, {"measure": "Mean Number of Puffs of Rescue Medication During the Whole Day", "description": "Mean of daily use of salbutamol (albuterol) rescue medication as needed during the entire study period. Assessed by patients at home using the AM2+ device (overall means obtained during each period of randomised treatment excluding the data of the first 2 weeks will be compared). Means are adjusted for treatment, period, patient and study baseline.", "timeFrame": "2-4 weeks"}, {"measure": "Percentage of Asthma Symptom Free Days", "description": "Percentage of asthma-symptom free days after the first 2 weeks of each treatment period was calculated as the number of symptom-free days divided by the number of days on treatment multiplied by 100. A symptom-free day was defined as a day in which no asthma symptoms were recorded, no rescue medication was recorded, activities during the day were not at all limited due to asthma, no shortness of breath during the day was recorded, no wheezing or coughing during the day and no night-time awakenings due to asthma were recorded. Assessed by patients at home using the AM2+ device.", "timeFrame": "2-4 weeks"}, {"measure": "Number of Patients Categorized by Highest Number of Night Time Awakenings (Overall)", "description": "Assessed by patients at home using the AM2+ device after the first 2 weeks of each period of randomised treatment.", "timeFrame": "2-4 weeks"}, {"measure": "Number of Patients Categorized by Worst Asthma Daytime Symptoms (Overall)", "description": "Assessed by patients at home using the AM2+ device after the first 2 weeks of each period of randomised treatment.", "timeFrame": "2-4 weeks"}, {"measure": "Number of Patients Categorized by Worst Asthma Nighttime Symptoms (Overall)", "description": "Assessed by patients at home using the AM2+ device after the first 2 weeks of each period of randomised treatment.", "timeFrame": "2-4 weeks"}, {"measure": "Total Asthma Quality of Life Questionnaire (AQLQ(s)) Score", "description": "Total score from the Standardised Asthma Quality of Life Questionnaire (AQLQ (s)) at the end of each 4 week treatment period. The AQLQ(s) contains 32 questions, each question has a 7 point scale from 1 (highest intensity) till 7 (no symptoms). Total score was defined as the sum of all items divided by the number of items.", "timeFrame": "4 weeks"}, {"measure": "Total Asthma Control Questionnaire (ACQ) Score", "description": "Control of asthma as assessed by the ACQ at the end of each 4-week treatment period.The ACQ contains 7 questions, each question has a 7 point scale from 0 (no symptoms) till 6 (highest intensity). Total score was defined as the sum of all items divided by the number of items.", "timeFrame": "4 weeks"}, {"measure": "Potassium 1 Hour Pre-dose", "description": "Effect on potassium evaluated 1 hour pre-dose. Analysis is based on the log of the potassium values. For the geometric means, the results were back-transformed to the original scale.", "timeFrame": "4 weeks"}, {"measure": "Potassium 1 Hour Post-dose", "description": "Effect on potassium evaluated 1 hour post-dose. Analysis is based on the log of the potassium values. For the geometric means, the results were back-transformed to the original scale.", "timeFrame": "4 weeks"}, {"measure": "Potassium 3 Hours Post-dose", "description": "Effect on potassium evaluated 3 hours post-dose. Analysis is based on the log of the potassium values. For the geometric means, the results were back-transformed to the original scale.", "timeFrame": "4 weeks"}, {"measure": "Clinical Relevant Abnormalities for Vital Signs, Blood Chemistry, Haematology, Urinalysis and ECG", "description": "Clinical relevant abnormalities for Vital Signs, Blood Chemistry, Haematology, Urinalysis and ECG. New abnormal findings or worsening of baseline conditions were reported as Adverse Events.", "timeFrame": "4 weeks"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion criteria:\n\n1. All patients must sign an informed consent consistent with International Conference on Harmonisation-Good Clinical Practice (ICH-GCP) guidelines prior to participation in the trial, i.e. prior to any study procedures which includes medication washout and restrictions. A separate informed consent is required for pharmacogenomic sampling.\n2. Male or female patients, aged between 18 and 70 years of age, diurnally active\n3. A history of asthma diagnosed by physician at least 3 months prior to Visit 1 at GINA treatment steps 3 or 4. The diagnosis of asthma must have been made before the age of 40.\n4. Pre-bronchodilator FEV1 between 60% predicted and 90% predicted at Visit 1.\n5. Increase in FEV1 greater or equal to 12% and 200 ml 15 minutes after 400mcg salbutamol (albuterol) at Visit 1.\n6. Patient must have been taking inhaled corticosteroids (ICS) for at least 12 weeks prior to screening, and must have been receiving at a stable dose for at least 6 weeks prior to screening either: - a medium to high dose ICS or - a low to high dose ICS in combination with Long acting beta agonist (LABA).\n7. All patients must be symptomatic.\n\nExclusion criteria:\n\n1. Patients with a significant disease other than asthma; a significant disease is defined as a disease which, in the opinion of the investigator, may (i) put the patient at risk because of participation in the study, (ii) influence the results of the study, or (iii) cause concern regarding the patient's ability to participate in the study\n2. Patients who have been hospitalised for an asthma exacerbation within 3 months or had an admission to an intensive care unit for asthma within 3 years of Visit 1\n3. Patients will be excluded when they have: - an aspartate aminotransferase (AST) \\>80 IU/L, alanine aminotransferase (ALT) \\>80 IU/L, bilirubin \\>1.5 X upper limit of normal (ULN) or creatinine \\>1.5 X ULN - clinically relevant abnormal baseline haematology, blood chemistry, or urinalysis\n4. Patients with any of the following conditions: - a diagnosis of thyrotoxicosis\n\n   * a diagnosis of paroxysmal tachycardia (\\>100 beats per minute)\n   * a marked baseline prolongation of QT/QTc interval at Visit 1 (e.g., repeated demonstration of a QTc interval \\>450 ms) as recommended by ICH E14\n   * a history of additional risk factors for Torsade de Pointes (TdP) (e.g., heart failure, hypokalemia, family history of Long QT Syndrome) as recommended by ICH E14.\n5. Patients with any of the following conditions: - a history of myocardial infarction within 1 year of screening visit (Visit 1)\n\n   * a diagnosis of clinically relevant cardiac arrhythmia\n   * a history of cor pulmonale\n   * known active tuberculosis\n   * a malignancy for which patient has undergone resection, radiation therapy or chemotherapy within last five years (patients with treated basal cell carcinoma are allowed)\n   * a history of life-threatening pulmonary obstruction\n   * a history of chronic obstructive pulmonary disease\n   * history of cystic fibrosis\n   * clinically evident bronchiectasis\n   * a history of significant alcohol or drug abuse", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "70 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Boehringer Ingelheim", "affiliation": "Boehringer Ingelheim", "role": "STUDY_CHAIR"}], "locations": [{"facility": "1222.27.43002 Boehringer Ingelheim Investigational Site", "city": "Linz", "country": "Austria", "geoPoint": {"lat": 48.30639, "lon": 14.28611}}, {"facility": "1222.27.43004 Boehringer Ingelheim Investigational Site", "city": "Schl\u00fcsslberg", "country": "Austria", "geoPoint": {"lat": 48.21861, "lon": 13.87161}}, {"facility": "1222.27.43001 Boehringer Ingelheim Investigational Site", "city": "Thalheim bei Wels", "country": "Austria", "geoPoint": {"lat": 48.15, "lon": 14.03333}}, {"facility": "1222.27.43003 Boehringer Ingelheim Investigational Site", "city": "Wien", "country": "Austria", "geoPoint": {"lat": 48.20849, "lon": 16.37208}}, {"facility": "1222.27.49003 Boehringer Ingelheim Investigational Site", "city": "Berlin", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "1222.27.49004 Boehringer Ingelheim Investigational Site", "city": "Berlin", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "1222.27.49009 Boehringer Ingelheim Investigational Site", "city": "Berlin", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "1222.27.49011 Boehringer Ingelheim Investigational Site", "city": "Frankfurt", "country": "Germany", "geoPoint": {"lat": 50.11552, "lon": 8.68417}}, {"facility": "1222.27.49008 Boehringer Ingelheim Investigational Site", "city": "Hannover", "country": "Germany", "geoPoint": {"lat": 52.37052, "lon": 9.73322}}, {"facility": "1222.27.49002 Boehringer Ingelheim Investigational Site", "city": "L\u00fcbeck", "country": "Germany", "geoPoint": {"lat": 53.86893, "lon": 10.68729}}, {"facility": "1222.27.49007 Boehringer Ingelheim Investigational Site", "city": "R\u00fcdersdorf", "country": "Germany", "geoPoint": {"lat": 51.1, "lon": 11.45}}, {"facility": "1222.27.49006 Boehringer Ingelheim Investigational Site", "city": "Wiesbaden", "country": "Germany", "geoPoint": {"lat": 50.08258, "lon": 8.24932}}, {"facility": "1222.27.49010 Boehringer Ingelheim Investigational Site", "city": "Wiesloch", "country": "Germany", "geoPoint": {"lat": 49.29504, "lon": 8.69846}}, {"facility": "1222.27.48001 Boehringer Ingelheim Investigational Site", "city": "Lodz", "country": "Poland", "geoPoint": {"lat": 51.75, "lon": 19.46667}}, {"facility": "1222.27.48002 Boehringer Ingelheim Investigational Site", "city": "Lodz", "country": "Poland", "geoPoint": {"lat": 51.75, "lon": 19.46667}}, {"facility": "1222.27.48003 Boehringer Ingelheim Investigational Site", "city": "Poznan", "country": "Poland", "geoPoint": {"lat": 52.40692, "lon": 16.92993}}, {"facility": "1222.27.48004 Boehringer Ingelheim Investigational Site", "city": "Proszowice", "country": "Poland", "geoPoint": {"lat": 50.19275, "lon": 20.28909}}, {"facility": "1222.27.40002 Boehringer Ingelheim Investigational Site", "city": "Bucharest", "country": "Romania", "geoPoint": {"lat": 44.43225, "lon": 26.10626}}, {"facility": "1222.27.40003 Boehringer Ingelheim Investigational Site", "city": "Bucharest", "country": "Romania", "geoPoint": {"lat": 44.43225, "lon": 26.10626}}, {"facility": "1222.27.42101 Boehringer Ingelheim Investigational Site", "city": "Bardejov", "country": "Slovakia", "geoPoint": {"lat": 49.29175, "lon": 21.27271}}, {"facility": "1222.27.42103 Boehringer Ingelheim Investigational Site", "city": "Lucenec", "country": "Slovakia", "geoPoint": {"lat": 48.33249, "lon": 19.66708}}, {"facility": "1222.27.42104 Boehringer Ingelheim Investigational Site", "city": "Martin", "country": "Slovakia", "geoPoint": {"lat": 49.06651, "lon": 18.92399}}, {"facility": "1222.27.42102 Boehringer Ingelheim Investigational Site", "city": "Spisska Nova Ves", "country": "Slovakia", "geoPoint": {"lat": 48.94464, "lon": 20.56153}}, {"facility": "1222.27.38601 Boehringer Ingelheim Investigational Site", "city": "Golnik", "country": "Slovenia", "geoPoint": {"lat": 46.33333, "lon": 14.33333}}, {"facility": "1222.27.38603 Boehringer Ingelheim Investigational Site", "city": "Hoce", "country": "Slovenia"}, {"facility": "1222.27.38605 Boehringer Ingelheim Investigational Site", "city": "Kamnik", "country": "Slovenia", "geoPoint": {"lat": 46.22587, "lon": 14.61207}}, {"facility": "1222.27.38604 Boehringer Ingelheim Investigational Site", "city": "Topolsica", "country": "Slovenia", "geoPoint": {"lat": 46.40028, "lon": 15.02157}}]}, "referencesModule": {"references": [{"pmid": "26283085", "type": "DERIVED", "citation": "O'Byrne PM, D'Urzo T, Beck E, Flezar M, Gahlemann M, Hart L, Blahova Z, Toorawa R, Beeh KM. Dose-finding evaluation of once-daily treatment with olodaterol, a novel long-acting beta2-agonist, in patients with asthma: results of a parallel-group study and a crossover study. Respir Res. 2015 Aug 18;16(1):97. doi: 10.1186/s12931-015-0249-8."}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Study Total", "description": "This was a randomised, double-blind, double dummy, placebo- and active-controlled, 6 treatment, 4 period incomplete crossover trial. 198 patients were assigned randomly to one of 30 treatment sequences, each sequence comprising 4 out of the 6 treatments listed: one of four doses (20 microgram (mcg), 10 mcg, 5 mcg or 2 mcg) of Olodaterol (Olo) once daily (qd) delivered via the Respimat inhaler or Foradil (Form) 12 mcg twice daily (bid) delivered via the Aerolizer inhaler or equivalent placebo. The duration of each treatment period was 4 weeks with no washout periods between treatments."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "comment": "Entered and treated", "numSubjects": "198"}]}, {"type": "Received Placebo", "achievements": [{"groupId": "FG000", "numSubjects": "125"}]}, {"type": "Received Olo 2 mcg qd", "achievements": [{"groupId": "FG000", "numSubjects": "121"}]}, {"type": "Received Olo 5 mcg qd", "achievements": [{"groupId": "FG000", "numSubjects": "130"}]}, {"type": "Received Olo 10 mcg qd", "achievements": [{"groupId": "FG000", "numSubjects": "127"}]}, {"type": "Received Olo 20 mcg qd", "achievements": [{"groupId": "FG000", "numSubjects": "124"}]}, {"type": "Received Form 12 mcg Bid", "achievements": [{"groupId": "FG000", "numSubjects": "125"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "182"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "16"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "8"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "3"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "1"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "2"}]}, {"type": "Other", "reasons": [{"groupId": "FG000", "numSubjects": "2"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Study Total", "description": "This was a randomised, double-blind, double dummy, placebo- and active-controlled, 6 treatment, 4 period incomplete crossover trial. 198 patients were assigned randomly to one of 30 treatment sequences, each sequence comprising 4 out of the 6 treatments listed: one of four doses (20 microgram (mcg), 10 mcg, 5 mcg or 2 mcg) of Olodaterol (Olo) once daily (qd) delivered via the Respimat inhaler or Foradil (Form) 12 mcg twice daily (bid) delivered via the Aerolizer inhaler or equivalent placebo. The duration of each treatment period was 4 weeks with no washout periods between treatments."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "198"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "45.0", "spread": "11.8"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "112"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "86"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Forced Expiratory Volume in 1 Second (FEV1) Area Under Curve 0-24 Hours (AUC 0-24h) Response at the End of Each Treatment Period", "description": "Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values at the randomisation visit. Means are adjusted for treatment, period, patient and study baseline. FEV1 AUC 0-24h was calculated from 0-24 hours post-dose using the trapezoidal rule, divided by the observation time (24h) to report in litres.", "populationDescription": "Full analysis set (FAS). FAS is defined as all patients in the treated set for whom the baseline (pre-dose) value is available, and who have a value for the primary endpoint for at least one crossover period.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Liter", "timeFrame": "1 hour (h) prior and 10 minutes (min) prior to first dose (baseline) and -1 h, -10 mins, 30 min, 60 min, 2 h, 3 h, 4 h, 11 h 50 min, 12 h 30 min, 13 h, 14 h, 15 h, 16 h, 18 h, 20 h, 22 h, 23 h, and 23 h 50 min related to evening dose after 4 weeks", "groups": [{"id": "OG000", "title": "Placebo", "description": "Equivalent Placebo (morning and evening) delivered by the matching Inhaler (Respimat or Aerolizer)."}, {"id": "OG001", "title": "Olo 2 mcg qd", "description": "Olodaterol 2 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler."}, {"id": "OG002", "title": "Olo 5 mcg qd", "description": "Olodaterol 5 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler."}, {"id": "OG003", "title": "Olo 10 mcg qd", "description": "Olodaterol 10 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler."}, {"id": "OG004", "title": "Olo 20 mcg qd", "description": "Olodaterol 20 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler."}, {"id": "OG005", "title": "Form 12 mcg Bid", "description": "Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "122"}, {"groupId": "OG001", "value": "119"}, {"groupId": "OG002", "value": "126"}, {"groupId": "OG003", "value": "121"}, {"groupId": "OG004", "value": "119"}, {"groupId": "OG005", "value": "122"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.004", "spread": "0.025"}, {"groupId": "OG001", "value": "0.135", "spread": "0.025"}, {"groupId": "OG002", "value": "0.178", "spread": "0.025"}, {"groupId": "OG003", "value": "0.201", "spread": "0.025"}, {"groupId": "OG004", "value": "0.225", "spread": "0.025"}, {"groupId": "OG005", "value": "0.164", "spread": "0.025"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Mean Difference (Final Values)", "paramValue": "0.140", "ciPctValue": "95", "ciLowerLimit": "0.097", "ciUpperLimit": "0.182", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.022", "estimateComment": "Olo 2 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Mean Difference (Final Values)", "paramValue": "0.182", "ciPctValue": "95", "ciLowerLimit": "0.140", "ciUpperLimit": "0.224", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.021", "estimateComment": "Olo 5 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Mean Difference (Final Values)", "paramValue": "0.205", "ciPctValue": "95", "ciLowerLimit": "0.163", "ciUpperLimit": "0.248", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.022", "estimateComment": "Olo 10 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG004"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Mean Difference (Final Values)", "paramValue": "0.229", "ciPctValue": "95", "ciLowerLimit": "0.186", "ciUpperLimit": "0.272", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.022", "estimateComment": "Olo 20 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG005"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Mean Difference (Final Values)", "paramValue": "0.169", "ciPctValue": "95", "ciLowerLimit": "0.126", "ciUpperLimit": "0.211", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.022", "estimateComment": "Form 12 mcg bid minus Placebo"}]}, {"type": "SECONDARY", "title": "FEV1 Area Under Curve 0-12 h (AUC 0-12h) Response at the End of Each Treatment Period", "description": "Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values at the randomisation visit. Means are adjusted for treatment, period, patient and study baseline. FEV1 AUC 0-12h was calculated from 0-12 hours post-dose using the trapezoidal rule, divided by the observation time (12h) to report in litres.", "populationDescription": "FAS", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Liter", "timeFrame": "1 hour (h) prior and 10 minutes (min) prior to first dose (baseline) and -1 h, -10 mins, 30 min, 60 min, 2 h, 3 h, 4 h, 11 h 50 min related to evening dose after 4 weeks", "groups": [{"id": "OG000", "title": "Placebo", "description": "Equivalent Placebo (morning and evening) delivered by the matching Inhaler (Respimat or Aerolizer)."}, {"id": "OG001", "title": "Olo 2 mcg qd", "description": "Olodaterol 2 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler."}, {"id": "OG002", "title": "Olo 5 mcg qd", "description": "Olodaterol 5 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler."}, {"id": "OG003", "title": "Olo 10 mcg qd", "description": "Olodaterol 10 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler."}, {"id": "OG004", "title": "Olo 20 mcg qd", "description": "Olodaterol 20 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler."}, {"id": "OG005", "title": "Form 12 mcg Bid", "description": "Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "122"}, {"groupId": "OG001", "value": "119"}, {"groupId": "OG002", "value": "126"}, {"groupId": "OG003", "value": "121"}, {"groupId": "OG004", "value": "119"}, {"groupId": "OG005", "value": "122"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.039", "spread": "0.026"}, {"groupId": "OG001", "value": "0.124", "spread": "0.026"}, {"groupId": "OG002", "value": "0.173", "spread": "0.026"}, {"groupId": "OG003", "value": "0.194", "spread": "0.026"}, {"groupId": "OG004", "value": "0.211", "spread": "0.026"}, {"groupId": "OG005", "value": "0.145", "spread": "0.026"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Mean Difference (Final Values)", "paramValue": "0.163", "ciPctValue": "95", "ciLowerLimit": "0.116", "ciUpperLimit": "0.211", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.024", "estimateComment": "Olo 2 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Mean Difference (Final Values)", "paramValue": "0.212", "ciPctValue": "95", "ciLowerLimit": "0.166", "ciUpperLimit": "0.259", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.024", "estimateComment": "Olo 5 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Mean Difference (Final Values)", "paramValue": "0.233", "ciPctValue": "95", "ciLowerLimit": "0.186", "ciUpperLimit": "0.280", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.024", "estimateComment": "Olo 10 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG004"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Mean Difference (Final Values)", "paramValue": "0.250", "ciPctValue": "95", "ciLowerLimit": "0.203", "ciUpperLimit": "0.298", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.024", "estimateComment": "Olo 20 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG005"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Mean Difference (Final Values)", "paramValue": "0.184", "ciPctValue": "95", "ciLowerLimit": "0.137", "ciUpperLimit": "0.231", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.024", "estimateComment": "Form 12 mcg bid minus Placebo"}]}, {"type": "SECONDARY", "title": "FEV1 Area Under Curve 12-24 h (AUC 12-24h) Response at the End of Each Treatment Period", "description": "Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values at the randomisation visit. Means are adjusted for treatment, period, patient and study baseline. FEV1 AUC 12-24h was calculated from 12-24 hours post-dose using the trapezoidal rule, divided by the observation time (12h) to report in litres.", "populationDescription": "FAS", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Liter", "timeFrame": "1 hour (h) prior and 10 minutes (min) prior to first dose (baseline) and 11 h 50 min, 12 h 30 min, 13 h, 14 h, 15 h, 16 h, 18 h, 20 h, 22 h, 23 h, and 23 h 50 min related to evening dose after 4 weeks", "groups": [{"id": "OG000", "title": "Placebo", "description": "Equivalent Placebo (morning and evening) delivered by the matching Inhaler (Respimat or Aerolizer)."}, {"id": "OG001", "title": "Olo 2 mcg qd", "description": "Olodaterol 2 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler."}, {"id": "OG002", "title": "Olo 5 mcg qd", "description": "Olodaterol 5 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler."}, {"id": "OG003", "title": "Olo 10 mcg qd", "description": "Olodaterol 10 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler."}, {"id": "OG004", "title": "Olo 20 mcg qd", "description": "Olodaterol 20 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler."}, {"id": "OG005", "title": "Form 12 mcg Bid", "description": "Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "122"}, {"groupId": "OG001", "value": "119"}, {"groupId": "OG002", "value": "126"}, {"groupId": "OG003", "value": "121"}, {"groupId": "OG004", "value": "119"}, {"groupId": "OG005", "value": "122"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.031", "spread": "0.026"}, {"groupId": "OG001", "value": "0.147", "spread": "0.026"}, {"groupId": "OG002", "value": "0.183", "spread": "0.025"}, {"groupId": "OG003", "value": "0.208", "spread": "0.026"}, {"groupId": "OG004", "value": "0.238", "spread": "0.026"}, {"groupId": "OG005", "value": "0.183", "spread": "0.026"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Mean Difference (Final Values)", "paramValue": "0.115", "ciPctValue": "95", "ciLowerLimit": "0.073", "ciUpperLimit": "0.158", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.022", "estimateComment": "Olo 2 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Mean Difference (Final Values)", "paramValue": "0.151", "ciPctValue": "95", "ciLowerLimit": "0.110", "ciUpperLimit": "0.193", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.021", "estimateComment": "Olo 5 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Mean Difference (Final Values)", "paramValue": "0.177", "ciPctValue": "95", "ciLowerLimit": "0.135", "ciUpperLimit": "0.219", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.022", "estimateComment": "Olo 10 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG004"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Mean Difference (Final Values)", "paramValue": "0.207", "ciPctValue": "95", "ciLowerLimit": "0.164", "ciUpperLimit": "0.250", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.022", "estimateComment": "Olo 20 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG005"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Mean Difference (Final Values)", "paramValue": "0.152", "ciPctValue": "95", "ciLowerLimit": "0.110", "ciUpperLimit": "0.194", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.022", "estimateComment": "Form 12 mcg bid minus Placebo"}]}, {"type": "SECONDARY", "title": "Peak FEV1 Within 24 Hours Post-dose Response", "description": "Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values at the randomisation visit. Peak FEV1 within 24 hours post dose measured following the evening trial drug inhalation at the end of each 4 week period of randomised treatment. Means are adjusted for treatment, period, patient and study baseline.", "populationDescription": "FAS", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Liter", "timeFrame": "1 hour (h) prior and 10 minutes (min) prior to first dose (baseline) and 30 min, 60 min, 2 h, 3 h, 4 h, 11 h 50 min, 12 h 30 min, 13 h, 14 h, 15 h, 16 h, 18 h, 20 h, 22 h, 23 h, and 23 h 50 min related to evening dose after 4 weeks", "groups": [{"id": "OG000", "title": "Placebo", "description": "Equivalent Placebo (morning and evening) delivered by the matching Inhaler (Respimat or Aerolizer)."}, {"id": "OG001", "title": "Olo 2 mcg qd", "description": "Olodaterol 2 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler."}, {"id": "OG002", "title": "Olo 5 mcg qd", "description": "Olodaterol 5 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler."}, {"id": "OG003", "title": "Olo 10 mcg qd", "description": "Olodaterol 10 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler."}, {"id": "OG004", "title": "Olo 20 mcg qd", "description": "Olodaterol 20 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler."}, {"id": "OG005", "title": "Form 12 mcg Bid", "description": "Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "122"}, {"groupId": "OG001", "value": "119"}, {"groupId": "OG002", "value": "126"}, {"groupId": "OG003", "value": "121"}, {"groupId": "OG004", "value": "119"}, {"groupId": "OG005", "value": "122"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.224", "spread": "0.026"}, {"groupId": "OG001", "value": "0.326", "spread": "0.027"}, {"groupId": "OG002", "value": "0.359", "spread": "0.026"}, {"groupId": "OG003", "value": "0.385", "spread": "0.027"}, {"groupId": "OG004", "value": "0.404", "spread": "0.027"}, {"groupId": "OG005", "value": "0.390", "spread": "0.026"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Mean Difference (Final Values)", "paramValue": "0.102", "ciPctValue": "95", "ciLowerLimit": "0.056", "ciUpperLimit": "0.148", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.023", "estimateComment": "Olo 2 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Mean Difference (Final Values)", "paramValue": "0.135", "ciPctValue": "95", "ciLowerLimit": "0.090", "ciUpperLimit": "0.180", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.023", "estimateComment": "Olo 5 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Mean Difference (Final Values)", "paramValue": "0.161", "ciPctValue": "95", "ciLowerLimit": "0.116", "ciUpperLimit": "0.207", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.023", "estimateComment": "Olo 10 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG004"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Mean Difference (Final Values)", "paramValue": "0.180", "ciPctValue": "95", "ciLowerLimit": "0.134", "ciUpperLimit": "0.226", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.023", "estimateComment": "Olo 20 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG005"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Mean Difference (Final Values)", "paramValue": "0.166", "ciPctValue": "95", "ciLowerLimit": "0.120", "ciUpperLimit": "0.211", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.023", "estimateComment": "Form 12 mcg bid minus Placebo"}]}, {"type": "SECONDARY", "title": "Trough FEV1 Response", "description": "Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values at the randomisation visit. Trough values were defined as the mean of 2 FEV1 values performed at the planned timepoints 23h and 23h 50min related to evening trial-drug inhalation at the end of each 4 week period of randomised treatment. Means are adjusted for treatment, period, patient and study baseline.", "populationDescription": "FAS", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Liter", "timeFrame": "1 hour (h) prior and 10 minutes (min) prior to first dose (baseline) and 23 h, and 23 h 50 min related to evening dose after 4 weeks", "groups": [{"id": "OG000", "title": "Placebo", "description": "Equivalent Placebo (morning and evening) delivered by the matching Inhaler (Respimat or Aerolizer)."}, {"id": "OG001", "title": "Olo 2 mcg qd", "description": "Olodaterol 2 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler."}, {"id": "OG002", "title": "Olo 5 mcg qd", "description": "Olodaterol 5 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler."}, {"id": "OG003", "title": "Olo 10 mcg qd", "description": "Olodaterol 10 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler."}, {"id": "OG004", "title": "Olo 20 mcg qd", "description": "Olodaterol 20 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler."}, {"id": "OG005", "title": "Form 12 mcg Bid", "description": "Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "122"}, {"groupId": "OG001", "value": "119"}, {"groupId": "OG002", "value": "126"}, {"groupId": "OG003", "value": "121"}, {"groupId": "OG004", "value": "119"}, {"groupId": "OG005", "value": "122"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.013", "spread": "0.026"}, {"groupId": "OG001", "value": "0.116", "spread": "0.026"}, {"groupId": "OG002", "value": "0.146", "spread": "0.026"}, {"groupId": "OG003", "value": "0.182", "spread": "0.026"}, {"groupId": "OG004", "value": "0.211", "spread": "0.026"}, {"groupId": "OG005", "value": "0.115", "spread": "0.026"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Mean Difference (Final Values)", "paramValue": "0.103", "ciPctValue": "95", "ciLowerLimit": "0.058", "ciUpperLimit": "0.148", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.023", "estimateComment": "Olo 2 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Mean Difference (Final Values)", "paramValue": "0.133", "ciPctValue": "95", "ciLowerLimit": "0.088", "ciUpperLimit": "0.177", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.023", "estimateComment": "Olo 5 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Mean Difference (Final Values)", "paramValue": "0.169", "ciPctValue": "95", "ciLowerLimit": "0.124", "ciUpperLimit": "0.214", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.023", "estimateComment": "Olo 10 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG004"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Mean Difference (Final Values)", "paramValue": "0.199", "ciPctValue": "95", "ciLowerLimit": "0.153", "ciUpperLimit": "0.244", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.023", "estimateComment": "Olo 20 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG005"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Mean Difference (Final Values)", "paramValue": "0.103", "ciPctValue": "95", "ciLowerLimit": "0.058", "ciUpperLimit": "0.147", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.023", "estimateComment": "Form 12 mcg bid minus Placebo"}]}, {"type": "SECONDARY", "title": "Forced Vital Capacity (FVC) Area Under Curve 0-12 Hours (AUC 0-12h) Response", "description": "Response was defined as change from baseline. Study baseline FVC was defined as the mean of the available pre-dose FVC values at the randomisation visit. Means are adjusted for treatment, period, patient and study baseline. FVC AUC 0-12h was calculated using the trapezoidal rule, divided by the observation time to report in litres.", "populationDescription": "FAS", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Liter", "timeFrame": "1 hour (h) prior and 10 minutes (min) prior to first dose (baseline) and -1 h, -10 mins, 30 min, 60 min, 2 h , 3 h, 4 h, 11 h 50 min related to evening dose after 4 weeks", "groups": [{"id": "OG000", "title": "Placebo", "description": "Equivalent Placebo (morning and evening) delivered by the matching Inhaler (Respimat or Aerolizer)."}, {"id": "OG001", "title": "Olo 2 mcg qd", "description": "Olodaterol 2 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler."}, {"id": "OG002", "title": "Olo 5 mcg qd", "description": "Olodaterol 5 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler."}, {"id": "OG003", "title": "Olo 10 mcg qd", "description": "Olodaterol 10 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler."}, {"id": "OG004", "title": "Olo 20 mcg qd", "description": "Olodaterol 20 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler."}, {"id": "OG005", "title": "Form 12 mcg Bid", "description": "Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "122"}, {"groupId": "OG001", "value": "119"}, {"groupId": "OG002", "value": "126"}, {"groupId": "OG003", "value": "121"}, {"groupId": "OG004", "value": "119"}, {"groupId": "OG005", "value": "122"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.047", "spread": "0.029"}, {"groupId": "OG001", "value": "0.056", "spread": "0.029"}, {"groupId": "OG002", "value": "0.109", "spread": "0.029"}, {"groupId": "OG003", "value": "0.094", "spread": "0.029"}, {"groupId": "OG004", "value": "0.122", "spread": "0.029"}, {"groupId": "OG005", "value": "0.055", "spread": "0.029"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Mean Difference (Final Values)", "paramValue": "0.103", "ciPctValue": "95", "ciLowerLimit": "0.052", "ciUpperLimit": "0.154", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.026", "estimateComment": "Olo 2 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Mean Difference (Final Values)", "paramValue": "0.156", "ciPctValue": "95", "ciLowerLimit": "0.106", "ciUpperLimit": "0.207", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.026", "estimateComment": "Olo 5 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Mean Difference (Final Values)", "paramValue": "0.141", "ciPctValue": "95", "ciLowerLimit": "0.091", "ciUpperLimit": "0.192", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.026", "estimateComment": "Olo 10 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG004"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Mean Difference (Final Values)", "paramValue": "0.169", "ciPctValue": "95", "ciLowerLimit": "0.118", "ciUpperLimit": "0.221", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.026", "estimateComment": "Olo 20 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG005"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Mean Difference (Final Values)", "paramValue": "0.102", "ciPctValue": "95", "ciLowerLimit": "0.051", "ciUpperLimit": "0.153", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.026", "estimateComment": "Form 12 mcg bid minus Placebo"}]}, {"type": "SECONDARY", "title": "FVC Area Under Curve 12-24 Hours (AUC 12-24h) Response", "description": "Response was defined as change from baseline. Study baseline FVC was defined as the mean of the available pre-dose FVC values at the randomisation visit. Means are adjusted for treatment, period, patient and study baseline. FVC AUC 12-24h was calculated using the trapezoidal rule, divided by the observation time to report in litres.", "populationDescription": "FAS", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Liter", "timeFrame": "1 hour (h) prior and 10 minutes (min) prior to first dose (baseline) and 11 h 50 min, 12 h 30 min, 13 h, 14 h, 15 h, 16 h, 18 h, 20 h, 22 h, 23 h, and 23 h 50 min related to evening dose after 4 weeks", "groups": [{"id": "OG000", "title": "Placebo", "description": "Equivalent Placebo (morning and evening) delivered by the matching Inhaler (Respimat or Aerolizer)."}, {"id": "OG001", "title": "Olo 2 mcg qd", "description": "Olodaterol 2 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler."}, {"id": "OG002", "title": "Olo 5 mcg qd", "description": "Olodaterol 5 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler."}, {"id": "OG003", "title": "Olo 10 mcg qd", "description": "Olodaterol 10 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler."}, {"id": "OG004", "title": "Olo 20 mcg qd", "description": "Olodaterol 20 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler."}, {"id": "OG005", "title": "Form 12 mcg Bid", "description": "Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "122"}, {"groupId": "OG001", "value": "119"}, {"groupId": "OG002", "value": "126"}, {"groupId": "OG003", "value": "121"}, {"groupId": "OG004", "value": "119"}, {"groupId": "OG005", "value": "122"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.005", "spread": "0.029"}, {"groupId": "OG001", "value": "0.055", "spread": "0.029"}, {"groupId": "OG002", "value": "0.109", "spread": "0.028"}, {"groupId": "OG003", "value": "0.110", "spread": "0.029"}, {"groupId": "OG004", "value": "0.139", "spread": "0.029"}, {"groupId": "OG005", "value": "0.085", "spread": "0.029"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0107", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Mean Difference (Final Values)", "paramValue": "0.061", "ciPctValue": "95", "ciLowerLimit": "0.014", "ciUpperLimit": "0.107", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.024", "estimateComment": "Olo 2 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Mean Difference (Final Values)", "paramValue": "0.115", "ciPctValue": "95", "ciLowerLimit": "0.069", "ciUpperLimit": "0.160", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.023", "estimateComment": "Olo 5 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Mean Difference (Final Values)", "paramValue": "0.115", "ciPctValue": "95", "ciLowerLimit": "0.069", "ciUpperLimit": "0.161", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.024", "estimateComment": "Olo 10 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG004"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Mean Difference (Final Values)", "paramValue": "0.144", "ciPctValue": "95", "ciLowerLimit": "0.098", "ciUpperLimit": "0.191", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.024", "estimateComment": "Olo 20 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG005"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Mean Difference (Final Values)", "paramValue": "0.091", "ciPctValue": "95", "ciLowerLimit": "0.044", "ciUpperLimit": "0.137", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.024", "estimateComment": "Form 12 mcg bid minus Placebo"}]}, {"type": "SECONDARY", "title": "FVC Area Under Curve 0-24 Hours (AUC 0-24h) Response", "description": "Response was defined as change from baseline. Study baseline FVC was defined as the mean of the available pre-dose FVC values at the randomisation visit. Means are adjusted for treatment, period, patient and study baseline. FVC AUC 0-24h was calculated using the trapezoidal rule, divided by the observation time to report in litres.", "populationDescription": "FAS", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Liter", "timeFrame": "1 hour (h) prior and 10 minutes (min) prior to first dose (baseline) and -1 h, -10 min, 30 min, 60 min, 2 h, 3 h, 4 h, 11 h 50 min, 12 h 30 min, 13 h, 14 h, 15 h, 16 h, 18 h, 20 h, 22 h, 23 h, and 23 h 50 min related to evening dose after 4 weeks", "groups": [{"id": "OG000", "title": "Placebo", "description": "Equivalent Placebo (morning and evening) delivered by the matching Inhaler (Respimat or Aerolizer)."}, {"id": "OG001", "title": "Olo 2 mcg qd", "description": "Olodaterol 2 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler."}, {"id": "OG002", "title": "Olo 5 mcg qd", "description": "Olodaterol 5 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler."}, {"id": "OG003", "title": "Olo 10 mcg qd", "description": "Olodaterol 10 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler."}, {"id": "OG004", "title": "Olo 20 mcg qd", "description": "Olodaterol 20 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler."}, {"id": "OG005", "title": "Form 12 mcg Bid", "description": "Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "122"}, {"groupId": "OG001", "value": "119"}, {"groupId": "OG002", "value": "126"}, {"groupId": "OG003", "value": "121"}, {"groupId": "OG004", "value": "119"}, {"groupId": "OG005", "value": "122"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.026", "spread": "0.028"}, {"groupId": "OG001", "value": "0.056", "spread": "0.028"}, {"groupId": "OG002", "value": "0.109", "spread": "0.028"}, {"groupId": "OG003", "value": "0.102", "spread": "0.028"}, {"groupId": "OG004", "value": "0.131", "spread": "0.028"}, {"groupId": "OG005", "value": "0.070", "spread": "0.028"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0005", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Mean Difference (Final Values)", "paramValue": "0.082", "ciPctValue": "95", "ciLowerLimit": "0.036", "ciUpperLimit": "0.128", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.023", "estimateComment": "Olo 2 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Mean Difference (Final Values)", "paramValue": "0.136", "ciPctValue": "95", "ciLowerLimit": "0.090", "ciUpperLimit": "0.181", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.023", "estimateComment": "Olo 5 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Mean Difference (Final Values)", "paramValue": "0.128", "ciPctValue": "95", "ciLowerLimit": "0.083", "ciUpperLimit": "0.174", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.023", "estimateComment": "Olo 10 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG004"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Mean Difference (Final Values)", "paramValue": "0.157", "ciPctValue": "95", "ciLowerLimit": "0.111", "ciUpperLimit": "0.203", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.023", "estimateComment": "Olo 20 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG005"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Mean Difference (Final Values)", "paramValue": "0.097", "ciPctValue": "95", "ciLowerLimit": "0.051", "ciUpperLimit": "0.143", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.023", "estimateComment": "Form 12 mcg bid minus Placebo"}]}, {"type": "SECONDARY", "title": "Peak FVC Within 24 Hours Post-dose Response", "description": "Response was defined as change from baseline. Study baseline FVC was defined as the mean of the available pre-dose FVC values at the randomisation visit. Peak FVC within 24 hours post dose measured following the trial drug inhalation at the end of each 4 week period of randomised treatment. Means are adjusted for treatment, period, patient and study baseline.", "populationDescription": "FAS", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Liter", "timeFrame": "1 hour (h) prior and 10 minutes (min) prior to first dose (baseline) and 30 min, 60 min, 2 h, 3 h, 4 h, 11 h 50 min, 12 h 30 min, 13 h, 14 h, 15 h, 16 h, 18 h, 20 h, 22 h, 23 h, and 23 h 50 min related to evening dose after 4 weeks", "groups": [{"id": "OG000", "title": "Placebo", "description": "Equivalent Placebo (morning and evening) delivered by the matching Inhaler (Respimat or Aerolizer)."}, {"id": "OG001", "title": "Olo 2 mcg qd", "description": "Olodaterol 2 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler."}, {"id": "OG002", "title": "Olo 5 mcg qd", "description": "Olodaterol 5 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler."}, {"id": "OG003", "title": "Olo 10 mcg qd", "description": "Olodaterol 10 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler."}, {"id": "OG004", "title": "Olo 20 mcg qd", "description": "Olodaterol 20 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler."}, {"id": "OG005", "title": "Form 12 mcg Bid", "description": "Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "122"}, {"groupId": "OG001", "value": "119"}, {"groupId": "OG002", "value": "126"}, {"groupId": "OG003", "value": "121"}, {"groupId": "OG004", "value": "119"}, {"groupId": "OG005", "value": "122"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.253", "spread": "0.031"}, {"groupId": "OG001", "value": "0.300", "spread": "0.031"}, {"groupId": "OG002", "value": "0.356", "spread": "0.031"}, {"groupId": "OG003", "value": "0.342", "spread": "0.031"}, {"groupId": "OG004", "value": "0.380", "spread": "0.031"}, {"groupId": "OG005", "value": "0.326", "spread": "0.031"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0952", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Mean Difference (Final Values)", "paramValue": "0.048", "ciPctValue": "95", "ciLowerLimit": "-0.008", "ciUpperLimit": "0.103", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.028", "estimateComment": "Olo 2 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0003", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Mean Difference (Final Values)", "paramValue": "0.103", "ciPctValue": "95", "ciLowerLimit": "0.048", "ciUpperLimit": "0.158", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.028", "estimateComment": "Olo 5 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0016", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Mean Difference (Final Values)", "paramValue": "0.089", "ciPctValue": "95", "ciLowerLimit": "0.034", "ciUpperLimit": "0.145", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.028", "estimateComment": "Olo 10 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG004"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Mean Difference (Final Values)", "paramValue": "0.127", "ciPctValue": "95", "ciLowerLimit": "0.071", "ciUpperLimit": "0.183", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.028", "estimateComment": "Olo 20 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG005"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0096", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Mean Difference (Final Values)", "paramValue": "0.073", "ciPctValue": "95", "ciLowerLimit": "0.018", "ciUpperLimit": "0.129", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.028", "estimateComment": "Form 12 mcg bid minus Placebo"}]}, {"type": "SECONDARY", "title": "Trough FVC Response", "description": "Response was defined as change from baseline. Study baseline FVC was defined as the mean of the available pre-dose FVC values at the randomisation visit. Trough values were defined as the mean of 2 FEV1 values performed at the planned timepoints 23h and 23h 50min related to evening trial-drug inhalation at the end of each 4 week period of randomised treatment. Means are adjusted for treatment, period, patient and study baseline.", "populationDescription": "FAS", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Liter", "timeFrame": "1 hour (h) prior and 10 minutes (min) prior to first dose (baseline) and 23 h, and 23 h 50 min related to evening dose after 4 weeks", "groups": [{"id": "OG000", "title": "Placebo", "description": "Equivalent Placebo (morning and evening) delivered by the matching Inhaler (Respimat or Aerolizer)."}, {"id": "OG001", "title": "Olo 2 mcg qd", "description": "Olodaterol 2 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler."}, {"id": "OG002", "title": "Olo 5 mcg qd", "description": "Olodaterol 5 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler."}, {"id": "OG003", "title": "Olo 10 mcg qd", "description": "Olodaterol 10 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler."}, {"id": "OG004", "title": "Olo 20 mcg qd", "description": "Olodaterol 20 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler."}, {"id": "OG005", "title": "Form 12 mcg Bid", "description": "Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "122"}, {"groupId": "OG001", "value": "119"}, {"groupId": "OG002", "value": "126"}, {"groupId": "OG003", "value": "121"}, {"groupId": "OG004", "value": "119"}, {"groupId": "OG005", "value": "122"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.022", "spread": "0.029"}, {"groupId": "OG001", "value": "0.015", "spread": "0.029"}, {"groupId": "OG002", "value": "0.069", "spread": "0.029"}, {"groupId": "OG003", "value": "0.088", "spread": "0.029"}, {"groupId": "OG004", "value": "0.107", "spread": "0.029"}, {"groupId": "OG005", "value": "0.029", "spread": "0.029"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.1470", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Mean Difference (Final Values)", "paramValue": "0.037", "ciPctValue": "95", "ciLowerLimit": "-0.013", "ciUpperLimit": "0.088", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.026", "estimateComment": "Olo 2 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0003", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Mean Difference (Final Values)", "paramValue": "0.091", "ciPctValue": "95", "ciLowerLimit": "0.042", "ciUpperLimit": "0.141", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.025", "estimateComment": "Olo 5 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Mean Difference (Final Values)", "paramValue": "0.110", "ciPctValue": "95", "ciLowerLimit": "0.060", "ciUpperLimit": "0.160", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.025", "estimateComment": "Olo 10 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG004"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Mean Difference (Final Values)", "paramValue": "0.129", "ciPctValue": "95", "ciLowerLimit": "0.078", "ciUpperLimit": "0.179", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.026", "estimateComment": "Olo 20 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG005"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0448", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Mean Difference (Final Values)", "paramValue": "0.051", "ciPctValue": "95", "ciLowerLimit": "0.001", "ciUpperLimit": "0.101", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.025", "estimateComment": "Form 12 mcg bid minus Placebo"}]}, {"type": "SECONDARY", "title": "Peak Expiratory Flow (PEF) Area Under Curve 0-12 Hours (AUC 0-12h) Response", "description": "Response was defined as change from baseline. Study baseline PEF was defined as the mean of the available pre-dose PEF values at the randomisation visit. Means are adjusted for treatment, period, patient and study baseline. PEF AUC 0-12h was calculated using the trapezoidal rule, divided by the observation time to report in litres/seconds.", "populationDescription": "FAS", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Liter/sec", "timeFrame": "1 hour (h) prior and 10 minutes (min) prior to first dose (baseline) and -1 h, -10 mins, 30 min, 60 min, 2 h, 3 h, 4 h, 11 h 50 min related to evening dose after 4 weeks", "groups": [{"id": "OG000", "title": "Placebo", "description": "Equivalent Placebo (morning and evening) delivered by the matching Inhaler (Respimat or Aerolizer)."}, {"id": "OG001", "title": "Olo 2 mcg qd", "description": "Olodaterol 2 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler."}, {"id": "OG002", "title": "Olo 5 mcg qd", "description": "Olodaterol 5 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler."}, {"id": "OG003", "title": "Olo 10 mcg qd", "description": "Olodaterol 10 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler."}, {"id": "OG004", "title": "Olo 20 mcg qd", "description": "Olodaterol 20 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler."}, {"id": "OG005", "title": "Form 12 mcg Bid", "description": "Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "122"}, {"groupId": "OG001", "value": "119"}, {"groupId": "OG002", "value": "126"}, {"groupId": "OG003", "value": "121"}, {"groupId": "OG004", "value": "119"}, {"groupId": "OG005", "value": "122"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.117", "spread": "0.076"}, {"groupId": "OG001", "value": "0.291", "spread": "0.077"}, {"groupId": "OG002", "value": "0.449", "spread": "0.076"}, {"groupId": "OG003", "value": "0.495", "spread": "0.077"}, {"groupId": "OG004", "value": "0.553", "spread": "0.077"}, {"groupId": "OG005", "value": "0.471", "spread": "0.076"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Mean Difference (Final Values)", "paramValue": "0.408", "ciPctValue": "95", "ciLowerLimit": "0.277", "ciUpperLimit": "0.539", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.067", "estimateComment": "Olo 2 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Mean Difference (Final Values)", "paramValue": "0.566", "ciPctValue": "95", "ciLowerLimit": "0.438", "ciUpperLimit": "0.695", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.066", "estimateComment": "Olo 5 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Mean Difference (Final Values)", "paramValue": "0.612", "ciPctValue": "95", "ciLowerLimit": "0.482", "ciUpperLimit": "0.743", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.066", "estimateComment": "Olo 10 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG004"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Mean Difference (Final Values)", "paramValue": "0.670", "ciPctValue": "95", "ciLowerLimit": "0.539", "ciUpperLimit": "0.801", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.067", "estimateComment": "Olo 20 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG005"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Mean Difference (Final Values)", "paramValue": "0.588", "ciPctValue": "95", "ciLowerLimit": "0.457", "ciUpperLimit": "0.718", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.066", "estimateComment": "Form 12 mcg bid minus Placebo"}]}, {"type": "SECONDARY", "title": "PEF Area Under Curve 12-24 Hours (AUC 12-24h) Response", "description": "Response was defined as change from baseline. Study baseline PEF was defined as the mean of the available pre-dose PEF values at the randomisation visit. Means are adjusted for treatment, period, patient and study baseline. PEF AUC 12-24h was calculated using the trapezoidal rule, divided by the observation time to report in litres/seconds.", "populationDescription": "FAS", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Liter/sec", "timeFrame": "1 hour (h) prior and 10 minutes (min) prior to first dose (baseline) and 11 h 50 min, 12 h 30 min, 13 h, 14 h, 15 h, 16 h, 18 h, 20 h, 22 h, 23 h, and 23 h 50 min related to evening dose after 4 weeks", "groups": [{"id": "OG000", "title": "Placebo", "description": "Equivalent Placebo (morning and evening) delivered by the matching Inhaler (Respimat or Aerolizer)."}, {"id": "OG001", "title": "Olo 2 mcg qd", "description": "Olodaterol 2 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler."}, {"id": "OG002", "title": "Olo 5 mcg qd", "description": "Olodaterol 5 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler."}, {"id": "OG003", "title": "Olo 10 mcg qd", "description": "Olodaterol 10 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler."}, {"id": "OG004", "title": "Olo 20 mcg qd", "description": "Olodaterol 20 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler."}, {"id": "OG005", "title": "Form 12 mcg Bid", "description": "Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "122"}, {"groupId": "OG001", "value": "119"}, {"groupId": "OG002", "value": "126"}, {"groupId": "OG003", "value": "121"}, {"groupId": "OG004", "value": "119"}, {"groupId": "OG005", "value": "122"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.043", "spread": "0.075"}, {"groupId": "OG001", "value": "0.380", "spread": "0.075"}, {"groupId": "OG002", "value": "0.528", "spread": "0.075"}, {"groupId": "OG003", "value": "0.575", "spread": "0.075"}, {"groupId": "OG004", "value": "0.692", "spread": "0.075"}, {"groupId": "OG005", "value": "0.594", "spread": "0.075"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Mean Difference (Final Values)", "paramValue": "0.337", "ciPctValue": "95", "ciLowerLimit": "0.213", "ciUpperLimit": "0.461", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.063", "estimateComment": "Olo 2 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Mean Difference (Final Values)", "paramValue": "0.485", "ciPctValue": "95", "ciLowerLimit": "0.363", "ciUpperLimit": "0.606", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.062", "estimateComment": "Olo 5 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Mean Difference (Final Values)", "paramValue": "0.531", "ciPctValue": "95", "ciLowerLimit": "0.408", "ciUpperLimit": "0.655", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.063", "estimateComment": "Olo 10 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG004"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Mean Difference (Final Values)", "paramValue": "0.648", "ciPctValue": "95", "ciLowerLimit": "0.524", "ciUpperLimit": "0.772", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.063", "estimateComment": "Olo 20 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG005"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Mean Difference (Final Values)", "paramValue": "0.551", "ciPctValue": "95", "ciLowerLimit": "0.428", "ciUpperLimit": "0.674", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.063", "estimateComment": "Form 12 mcg bid minus Placebo"}]}, {"type": "SECONDARY", "title": "Peak Expiratory Flow (PEF) Area Under Curve 0-24 Hours (AUC 0-24h) Response", "description": "Response was defined as change from baseline. Study baseline PEF was defined as the mean of the available pre-dose PEF values at the randomisation visit. Means are adjusted for treatment, period, patient and study baseline. PEF AUC 0-24h was calculated using the trapezoidal rule, divided by the observation time to report in litres/seconds.", "populationDescription": "FAS", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Liter/sec", "timeFrame": "1 hour (h) prior and 10 minutes (min) prior to first dose (baseline) and -1h, -10 mins, 30 min, 60 min, 2 h, 3 h, 4 h, 11 h 50 min, 12 h 30 min, 13 h, 14 h, 15 h, 16 h, 18 h, 20 h, 22 h, 23 h, and 23 h 50 min related to evening dose after 4 weeks", "groups": [{"id": "OG000", "title": "Placebo", "description": "Equivalent Placebo (morning and evening) delivered by the matching Inhaler (Respimat or Aerolizer)."}, {"id": "OG001", "title": "Olo 2 mcg qd", "description": "Olodaterol 2 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler."}, {"id": "OG002", "title": "Olo 5 mcg qd", "description": "Olodaterol 5 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler."}, {"id": "OG003", "title": "Olo 10 mcg qd", "description": "Olodaterol 10 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler."}, {"id": "OG004", "title": "Olo 20 mcg qd", "description": "Olodaterol 20 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler."}, {"id": "OG005", "title": "Form 12 mcg Bid", "description": "Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "122"}, {"groupId": "OG001", "value": "119"}, {"groupId": "OG002", "value": "126"}, {"groupId": "OG003", "value": "121"}, {"groupId": "OG004", "value": "119"}, {"groupId": "OG005", "value": "122"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.038", "spread": "0.074"}, {"groupId": "OG001", "value": "0.336", "spread": "0.074"}, {"groupId": "OG002", "value": "0.489", "spread": "0.074"}, {"groupId": "OG003", "value": "0.534", "spread": "0.074"}, {"groupId": "OG004", "value": "0.623", "spread": "0.074"}, {"groupId": "OG005", "value": "0.532", "spread": "0.074"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Mean Difference (Final Values)", "paramValue": "0.373", "ciPctValue": "95", "ciLowerLimit": "0.253", "ciUpperLimit": "0.493", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.061", "estimateComment": "Olo 2 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Mean Difference (Final Values)", "paramValue": "0.527", "ciPctValue": "95", "ciLowerLimit": "0.409", "ciUpperLimit": "0.645", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.060", "estimateComment": "Olo 5 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Mean Difference (Final Values)", "paramValue": "0.572", "ciPctValue": "95", "ciLowerLimit": "0.453", "ciUpperLimit": "0.692", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.061", "estimateComment": "Olo 10 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG004"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Mean Difference (Final Values)", "paramValue": "0.660", "ciPctValue": "95", "ciLowerLimit": "0.540", "ciUpperLimit": "0.781", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.061", "estimateComment": "Olo 20 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG005"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Mean Difference (Final Values)", "paramValue": "0.570", "ciPctValue": "95", "ciLowerLimit": "0.451", "ciUpperLimit": "0.689", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.061", "estimateComment": "Form 12 mcg bid minus Placebo"}]}, {"type": "SECONDARY", "title": "Peak PEF Within 24 Hours Post-dose Response", "description": "Response was defined as change from baseline. Study baseline PEF was defined as the mean of the available pre-dose PEF values at the randomisation visit. Peak PEF within 24 hours post-dose measured following the evening trial drug inhalation at the end of each 4 week period of randomised treatment. Means are adjusted for treatment, period, patient and study baseline.", "populationDescription": "FAS", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Liter/sec", "timeFrame": "1 hour (h) prior and 10 minutes (min) prior to first dose (baseline) and 30 min, 60 min, 2 h, 3 h, 4 h, 11 h 50 min, 12 h 30 min, 13 h, 14 h, 15 h, 16 h, 18 h, 20 h, 22 h, 23 h, and 23 h 50 min related to evening dose after 4 weeks", "groups": [{"id": "OG000", "title": "Placebo", "description": "Equivalent Placebo (morning and evening) delivered by the matching Inhaler (Respimat or Aerolizer)."}, {"id": "OG001", "title": "Olo 2 mcg qd", "description": "Olodaterol 2 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler."}, {"id": "OG002", "title": "Olo 5 mcg qd", "description": "Olodaterol 5 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler."}, {"id": "OG003", "title": "Olo 10 mcg qd", "description": "Olodaterol 10 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler."}, {"id": "OG004", "title": "Olo 20 mcg qd", "description": "Olodaterol 20 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler."}, {"id": "OG005", "title": "Form 12 mcg Bid", "description": "Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "122"}, {"groupId": "OG001", "value": "119"}, {"groupId": "OG002", "value": "126"}, {"groupId": "OG003", "value": "121"}, {"groupId": "OG004", "value": "119"}, {"groupId": "OG005", "value": "122"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.664", "spread": "0.079"}, {"groupId": "OG001", "value": "0.966", "spread": "0.079"}, {"groupId": "OG002", "value": "1.093", "spread": "0.078"}, {"groupId": "OG003", "value": "1.130", "spread": "0.079"}, {"groupId": "OG004", "value": "1.198", "spread": "0.079"}, {"groupId": "OG005", "value": "1.168", "spread": "0.079"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Mean Difference (Final Values)", "paramValue": "0.302", "ciPctValue": "95", "ciLowerLimit": "0.168", "ciUpperLimit": "0.436", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.068", "estimateComment": "Olo 2 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Mean Difference (Final Values)", "paramValue": "0.429", "ciPctValue": "95", "ciLowerLimit": "0.297", "ciUpperLimit": "0.561", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.067", "estimateComment": "Olo 5 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Mean Difference (Final Values)", "paramValue": "0.466", "ciPctValue": "95", "ciLowerLimit": "0.333", "ciUpperLimit": "0.599", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.068", "estimateComment": "Olo 10 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG004"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Mean Difference (Final Values)", "paramValue": "0.534", "ciPctValue": "95", "ciLowerLimit": "0.400", "ciUpperLimit": "0.669", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.068", "estimateComment": "Olo 20 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG005"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Mean Difference (Final Values)", "paramValue": "0.504", "ciPctValue": "95", "ciLowerLimit": "0.371", "ciUpperLimit": "0.637", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.068", "estimateComment": "Form 12 mcg bid minus Placebo"}]}, {"type": "SECONDARY", "title": "Trough PEF Response", "description": "Response was defined as change from baseline. Study baseline PEF was defined as the mean of the available pre-dose PEF values at the randomisation visit. Trough values were defined as the mean of 2 FEV1 values performed at the planned timepoints 23h and 23h 50min related to evening trial-drug inhalation at the end of each 4 week period of randomised treatment. Means are adjusted for treatment, period, patient and study baseline.", "populationDescription": "FAS", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Liter/sec", "timeFrame": "1 hour (h) prior and 10 minutes (min) prior to first dose (baseline) and 23 h, and 23 h 50 min related to evening dose after 4 weeks", "groups": [{"id": "OG000", "title": "Placebo", "description": "Equivalent Placebo (morning and evening) delivered by the matching Inhaler (Respimat or Aerolizer)."}, {"id": "OG001", "title": "Olo 2 mcg qd", "description": "Olodaterol 2 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler."}, {"id": "OG002", "title": "Olo 5 mcg qd", "description": "Olodaterol 5 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler."}, {"id": "OG003", "title": "Olo 10 mcg qd", "description": "Olodaterol 10 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler."}, {"id": "OG004", "title": "Olo 20 mcg qd", "description": "Olodaterol 20 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler."}, {"id": "OG005", "title": "Form 12 mcg Bid", "description": "Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "122"}, {"groupId": "OG001", "value": "119"}, {"groupId": "OG002", "value": "126"}, {"groupId": "OG003", "value": "121"}, {"groupId": "OG004", "value": "119"}, {"groupId": "OG005", "value": "122"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.031", "spread": "0.078"}, {"groupId": "OG001", "value": "0.295", "spread": "0.078"}, {"groupId": "OG002", "value": "0.499", "spread": "0.077"}, {"groupId": "OG003", "value": "0.515", "spread": "0.078"}, {"groupId": "OG004", "value": "0.655", "spread": "0.078"}, {"groupId": "OG005", "value": "0.478", "spread": "0.078"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0002", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Mean Difference (Final Values)", "paramValue": "0.264", "ciPctValue": "95", "ciLowerLimit": "0.127", "ciUpperLimit": "0.401", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.070", "estimateComment": "Olo 2 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Mean Difference (Final Values)", "paramValue": "0.468", "ciPctValue": "95", "ciLowerLimit": "0.333", "ciUpperLimit": "0.602", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.069", "estimateComment": "Olo 5 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Mean Difference (Final Values)", "paramValue": "0.484", "ciPctValue": "95", "ciLowerLimit": "0.348", "ciUpperLimit": "0.620", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.069", "estimateComment": "Olo 10 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG004"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Mean Difference (Final Values)", "paramValue": "0.624", "ciPctValue": "95", "ciLowerLimit": "0.487", "ciUpperLimit": "0.761", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.070", "estimateComment": "Olo 20 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG005"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Mean Difference (Final Values)", "paramValue": "0.447", "ciPctValue": "95", "ciLowerLimit": "0.311", "ciUpperLimit": "0.583", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.069", "estimateComment": "Form 12 mcg bid minus Placebo"}]}, {"type": "SECONDARY", "title": "Mean Pre-dose Morning PEF (PEF a.m.)", "description": "PEF a.m. was measured by patients at home using the AM2+ device (overall means obtained during each period of randomised treatment excluding the data of the first 2 weeks will be compared). Means are adjusted for treatment, period, patient and study baseline.", "populationDescription": "FAS including all patients who contributed data for this endpoint.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Liter/min", "timeFrame": "2-4 weeks", "groups": [{"id": "OG000", "title": "Placebo", "description": "Equivalent Placebo (morning and evening) delivered by the matching Inhaler (Respimat or Aerolizer)."}, {"id": "OG001", "title": "Olo 2 mcg qd", "description": "Olodaterol 2 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler."}, {"id": "OG002", "title": "Olo 5 mcg qd", "description": "Olodaterol 5 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler."}, {"id": "OG003", "title": "Olo 10 mcg qd", "description": "Olodaterol 10 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler."}, {"id": "OG004", "title": "Olo 20 mcg qd", "description": "Olodaterol 20 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler."}, {"id": "OG005", "title": "Form 12 mcg Bid", "description": "Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "122"}, {"groupId": "OG001", "value": "119"}, {"groupId": "OG002", "value": "126"}, {"groupId": "OG003", "value": "123"}, {"groupId": "OG004", "value": "120"}, {"groupId": "OG005", "value": "123"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "361.89", "spread": "4.548"}, {"groupId": "OG001", "value": "383.90", "spread": "4.567"}, {"groupId": "OG002", "value": "390.91", "spread": "4.519"}, {"groupId": "OG003", "value": "389.78", "spread": "4.539"}, {"groupId": "OG004", "value": "394.82", "spread": "4.560"}, {"groupId": "OG005", "value": "385.42", "spread": "4.539"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Mean Difference (Final Values)", "paramValue": "22.012", "ciPctValue": "95", "ciLowerLimit": "14.802", "ciUpperLimit": "29.223", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "3.671", "estimateComment": "Olo 2 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Mean Difference (Final Values)", "paramValue": "29.022", "ciPctValue": "95", "ciLowerLimit": "21.931", "ciUpperLimit": "36.114", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "3.610", "estimateComment": "Olo 5 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Mean Difference (Final Values)", "paramValue": "27.887", "ciPctValue": "95", "ciLowerLimit": "20.755", "ciUpperLimit": "35.019", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "3.631", "estimateComment": "Olo 10 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG004"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Mean Difference (Final Values)", "paramValue": "32.935", "ciPctValue": "95", "ciLowerLimit": "25.730", "ciUpperLimit": "40.139", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "3.668", "estimateComment": "Olo 20 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG005"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Mean Difference (Final Values)", "paramValue": "23.528", "ciPctValue": "95", "ciLowerLimit": "16.371", "ciUpperLimit": "30.686", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "3.644", "estimateComment": "Form 12 mcg bid minus Placebo"}]}, {"type": "SECONDARY", "title": "Mean Pre-dose Evening PEF (PEF p.m.)", "description": "PEF p.m. was measured by patients at home using the AM2+ device (overall means obtained during each period of randomised treatment excluding the data of the first 2 weeks will be compared). Means are adjusted for treatment, period, patient and study baseline.", "populationDescription": "FAS including all patients who contributed data for this endpoint.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Liter/min", "timeFrame": "2-4 weeks", "groups": [{"id": "OG000", "title": "Placebo", "description": "Equivalent Placebo (morning and evening) delivered by the matching Inhaler (Respimat or Aerolizer)."}, {"id": "OG001", "title": "Olo 2 mcg qd", "description": "Olodaterol 2 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler."}, {"id": "OG002", "title": "Olo 5 mcg qd", "description": "Olodaterol 5 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler."}, {"id": "OG003", "title": "Olo 10 mcg qd", "description": "Olodaterol 10 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler."}, {"id": "OG004", "title": "Olo 20 mcg qd", "description": "Olodaterol 20 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler."}, {"id": "OG005", "title": "Form 12 mcg Bid", "description": "Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "122"}, {"groupId": "OG001", "value": "119"}, {"groupId": "OG002", "value": "126"}, {"groupId": "OG003", "value": "123"}, {"groupId": "OG004", "value": "120"}, {"groupId": "OG005", "value": "123"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "379.44", "spread": "4.398"}, {"groupId": "OG001", "value": "394.36", "spread": "4.418"}, {"groupId": "OG002", "value": "404.28", "spread": "4.368"}, {"groupId": "OG003", "value": "403.06", "spread": "4.389"}, {"groupId": "OG004", "value": "407.89", "spread": "4.410"}, {"groupId": "OG005", "value": "399.88", "spread": "4.389"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Mean Difference (Final Values)", "paramValue": "14.920", "ciPctValue": "95", "ciLowerLimit": "7.770", "ciUpperLimit": "22.071", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "3.640", "estimateComment": "Olo 2 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Mean Difference (Final Values)", "paramValue": "24.834", "ciPctValue": "95", "ciLowerLimit": "17.801", "ciUpperLimit": "31.866", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "3.580", "estimateComment": "Olo 5 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Mean Difference (Final Values)", "paramValue": "23.613", "ciPctValue": "95", "ciLowerLimit": "16.539", "ciUpperLimit": "30.686", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "3.601", "estimateComment": "Olo 10 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG004"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Mean Difference (Final Values)", "paramValue": "28.449", "ciPctValue": "95", "ciLowerLimit": "21.305", "ciUpperLimit": "35.594", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "3.637", "estimateComment": "Olo 20 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG005"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Mean Difference (Final Values)", "paramValue": "20.439", "ciPctValue": "95", "ciLowerLimit": "13.341", "ciUpperLimit": "27.538", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "3.614", "estimateComment": "Form 12 mcg bid minus Placebo"}]}, {"type": "SECONDARY", "title": "PEF Daily Variability", "description": "PEF daily variability was assessed by patients at home using the AM2+ device (overall means obtained during each period of randomised treatment excluding the data of the first 2 weeks will be compared). PEF daily variability is the absolute difference between the morning and the evening PEF value divided by the mean of these two values, expressed as a percent. Means are adjusted for treatment, period, patient and study baseline.", "populationDescription": "FAS including all patients who contributed data for this endpoint.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Percentage", "timeFrame": "2-4 weeks", "groups": [{"id": "OG000", "title": "Placebo", "description": "Equivalent Placebo (morning and evening) delivered by the matching Inhaler (Respimat or Aerolizer)."}, {"id": "OG001", "title": "Olo 2 mcg qd", "description": "Olodaterol 2 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler."}, {"id": "OG002", "title": "Olo 5 mcg qd", "description": "Olodaterol 5 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler."}, {"id": "OG003", "title": "Olo 10 mcg qd", "description": "Olodaterol 10 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler."}, {"id": "OG004", "title": "Olo 20 mcg qd", "description": "Olodaterol 20 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler."}, {"id": "OG005", "title": "Form 12 mcg Bid", "description": "Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "122"}, {"groupId": "OG001", "value": "119"}, {"groupId": "OG002", "value": "126"}, {"groupId": "OG003", "value": "122"}, {"groupId": "OG004", "value": "120"}, {"groupId": "OG005", "value": "123"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "11.688", "spread": "0.480"}, {"groupId": "OG001", "value": "9.694", "spread": "0.484"}, {"groupId": "OG002", "value": "9.593", "spread": "0.475"}, {"groupId": "OG003", "value": "9.851", "spread": "0.480"}, {"groupId": "OG004", "value": "9.899", "spread": "0.483"}, {"groupId": "OG005", "value": "10.417", "spread": "0.479"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Mean Difference (Final Values)", "paramValue": "-1.994", "ciPctValue": "95", "ciLowerLimit": "-2.989", "ciUpperLimit": "-0.999", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.507", "estimateComment": "Olo 2 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Mean Difference (Final Values)", "paramValue": "-2.095", "ciPctValue": "95", "ciLowerLimit": "-3.073", "ciUpperLimit": "-1.116", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.498", "estimateComment": "Olo 5 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0003", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Mean Difference (Final Values)", "paramValue": "-1.836", "ciPctValue": "95", "ciLowerLimit": "-2.824", "ciUpperLimit": "-0.849", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.503", "estimateComment": "Olo 10 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG004"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0004", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Mean Difference (Final Values)", "paramValue": "-1.789", "ciPctValue": "95", "ciLowerLimit": "-2.783", "ciUpperLimit": "-0.795", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.506", "estimateComment": "Olo 20 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG005"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0118", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Mean Difference (Final Values)", "paramValue": "-1.270", "ciPctValue": "95", "ciLowerLimit": "-2.258", "ciUpperLimit": "-0.283", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.503", "estimateComment": "Form 12 mcg bid minus Placebo"}]}, {"type": "SECONDARY", "title": "Mean Pre-dose Morning FEV1 (FEV1 a.m.)", "description": "FEV1 a.m. was measured by patients at home using the AM2+ device (overall means obtained during each period of randomised treatment excluding the data of the first 2 weeks will be compared). Means are adjusted for treatment, period, patient and study baseline.", "populationDescription": "FAS including all patients who contributed data for this endpoint.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "L", "timeFrame": "2-4 weeks", "groups": [{"id": "OG000", "title": "Placebo", "description": "Equivalent Placebo (morning and evening) delivered by the matching Inhaler (Respimat or Aerolizer)."}, {"id": "OG001", "title": "Olo 2 mcg qd", "description": "Olodaterol 2 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler."}, {"id": "OG002", "title": "Olo 5 mcg qd", "description": "Olodaterol 5 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler."}, {"id": "OG003", "title": "Olo 10 mcg qd", "description": "Olodaterol 10 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler."}, {"id": "OG004", "title": "Olo 20 mcg qd", "description": "Olodaterol 20 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler."}, {"id": "OG005", "title": "Form 12 mcg Bid", "description": "Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "122"}, {"groupId": "OG001", "value": "119"}, {"groupId": "OG002", "value": "126"}, {"groupId": "OG003", "value": "123"}, {"groupId": "OG004", "value": "120"}, {"groupId": "OG005", "value": "123"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2.309", "spread": "0.028"}, {"groupId": "OG001", "value": "2.402", "spread": "0.028"}, {"groupId": "OG002", "value": "2.438", "spread": "0.028"}, {"groupId": "OG003", "value": "2.445", "spread": "0.028"}, {"groupId": "OG004", "value": "2.479", "spread": "0.028"}, {"groupId": "OG005", "value": "2.403", "spread": "0.028"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0002", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Mean Difference (Final Values)", "paramValue": "0.093", "ciPctValue": "95", "ciLowerLimit": "0.045", "ciUpperLimit": "0.141", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.025", "estimateComment": "Olo 2 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Mean Difference (Final Values)", "paramValue": "0.128", "ciPctValue": "95", "ciLowerLimit": "0.081", "ciUpperLimit": "0.176", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.024", "estimateComment": "Olo 5 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Mean Difference (Final Values)", "paramValue": "0.135", "ciPctValue": "95", "ciLowerLimit": "0.087", "ciUpperLimit": "0.183", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.024", "estimateComment": "Olo 10 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG004"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Mean Difference (Final Values)", "paramValue": "0.169", "ciPctValue": "95", "ciLowerLimit": "0.121", "ciUpperLimit": "0.217", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.025", "estimateComment": "Olo 20 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG005"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Mean Difference (Final Values)", "paramValue": "0.093", "ciPctValue": "95", "ciLowerLimit": "0.045", "ciUpperLimit": "0.141", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.024", "estimateComment": "Form 12 mcg bid minus Placebo"}]}, {"type": "SECONDARY", "title": "Mean Pre-dose Evening FEV1 (FEV1 p.m.)", "description": "FEV1 p.m. was measured by patients at home using the AM2+ device (overall means obtained during each period of randomised treatment excluding the data of the first 2 weeks will be compared). Means are adjusted for treatment, period, patient and study baseline.", "populationDescription": "FAS including all patients who contributed data for this endpoint.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "L", "timeFrame": "2-4 weeks", "groups": [{"id": "OG000", "title": "Placebo", "description": "Equivalent Placebo (morning and evening) delivered by the matching Inhaler (Respimat or Aerolizer)."}, {"id": "OG001", "title": "Olo 2 mcg qd", "description": "Olodaterol 2 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler."}, {"id": "OG002", "title": "Olo 5 mcg qd", "description": "Olodaterol 5 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler."}, {"id": "OG003", "title": "Olo 10 mcg qd", "description": "Olodaterol 10 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler."}, {"id": "OG004", "title": "Olo 20 mcg qd", "description": "Olodaterol 20 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler."}, {"id": "OG005", "title": "Form 12 mcg Bid", "description": "Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "122"}, {"groupId": "OG001", "value": "119"}, {"groupId": "OG002", "value": "126"}, {"groupId": "OG003", "value": "123"}, {"groupId": "OG004", "value": "120"}, {"groupId": "OG005", "value": "123"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2.378", "spread": "0.027"}, {"groupId": "OG001", "value": "2.428", "spread": "0.027"}, {"groupId": "OG002", "value": "2.460", "spread": "0.027"}, {"groupId": "OG003", "value": "2.467", "spread": "0.027"}, {"groupId": "OG004", "value": "2.495", "spread": "0.027"}, {"groupId": "OG005", "value": "2.457", "spread": "0.027"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0362", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Mean Difference (Final Values)", "paramValue": "0.050", "ciPctValue": "95", "ciLowerLimit": "0.003", "ciUpperLimit": "0.097", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.024", "estimateComment": "Olo 2 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0006", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Mean Difference (Final Values)", "paramValue": "0.081", "ciPctValue": "95", "ciLowerLimit": "0.035", "ciUpperLimit": "0.127", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.023", "estimateComment": "Olo 5 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0002", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Mean Difference (Final Values)", "paramValue": "0.088", "ciPctValue": "95", "ciLowerLimit": "0.042", "ciUpperLimit": "0.135", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.024", "estimateComment": "Olo 10 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG004"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Mean Difference (Final Values)", "paramValue": "0.117", "ciPctValue": "95", "ciLowerLimit": "0.070", "ciUpperLimit": "0.164", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.024", "estimateComment": "Olo 20 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG005"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0010", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Mean Difference (Final Values)", "paramValue": "0.079", "ciPctValue": "95", "ciLowerLimit": "0.032", "ciUpperLimit": "0.125", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.024", "estimateComment": "Form 12 mcg bid minus Placebo"}]}, {"type": "SECONDARY", "title": "Mean Number of Puffs of Rescue Medication During the Whole Day", "description": "Mean of daily use of salbutamol (albuterol) rescue medication as needed during the entire study period. Assessed by patients at home using the AM2+ device (overall means obtained during each period of randomised treatment excluding the data of the first 2 weeks will be compared). Means are adjusted for treatment, period, patient and study baseline.", "populationDescription": "FAS including all patients who contributed data for this endpoint.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Number of Puffs", "timeFrame": "2-4 weeks", "groups": [{"id": "OG000", "title": "Placebo", "description": "Equivalent Placebo (morning and evening) delivered by the matching Inhaler (Respimat or Aerolizer)."}, {"id": "OG001", "title": "Olo 2 mcg qd", "description": "Olodaterol 2 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler."}, {"id": "OG002", "title": "Olo 5 mcg qd", "description": "Olodaterol 5 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler."}, {"id": "OG003", "title": "Olo 10 mcg qd", "description": "Olodaterol 10 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler."}, {"id": "OG004", "title": "Olo 20 mcg qd", "description": "Olodaterol 20 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler."}, {"id": "OG005", "title": "Form 12 mcg Bid", "description": "Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "122"}, {"groupId": "OG001", "value": "119"}, {"groupId": "OG002", "value": "126"}, {"groupId": "OG003", "value": "123"}, {"groupId": "OG004", "value": "120"}, {"groupId": "OG005", "value": "123"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.749", "spread": "0.130"}, {"groupId": "OG001", "value": "1.222", "spread": "0.130"}, {"groupId": "OG002", "value": "1.317", "spread": "0.128"}, {"groupId": "OG003", "value": "1.271", "spread": "0.129"}, {"groupId": "OG004", "value": "1.092", "spread": "0.130"}, {"groupId": "OG005", "value": "1.300", "spread": "0.129"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.526", "ciPctValue": "95", "ciLowerLimit": "-0.770", "ciUpperLimit": "-0.282", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.124", "estimateComment": "Olo 2 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0004", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.432", "ciPctValue": "95", "ciLowerLimit": "-0.671", "ciUpperLimit": "-0.192", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.122", "estimateComment": "Olo 5 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.478", "ciPctValue": "95", "ciLowerLimit": "-0.720", "ciUpperLimit": "-0.237", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.123", "estimateComment": "Olo 10 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG004"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.657", "ciPctValue": "95", "ciLowerLimit": "-0.901", "ciUpperLimit": "-0.413", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.124", "estimateComment": "Olo 20 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG005"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0003", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.449", "ciPctValue": "95", "ciLowerLimit": "-0.691", "ciUpperLimit": "-0.207", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.123", "estimateComment": "Form 12 mcg bid minus Placebo"}]}, {"type": "SECONDARY", "title": "Percentage of Asthma Symptom Free Days", "description": "Percentage of asthma-symptom free days after the first 2 weeks of each treatment period was calculated as the number of symptom-free days divided by the number of days on treatment multiplied by 100. A symptom-free day was defined as a day in which no asthma symptoms were recorded, no rescue medication was recorded, activities during the day were not at all limited due to asthma, no shortness of breath during the day was recorded, no wheezing or coughing during the day and no night-time awakenings due to asthma were recorded. Assessed by patients at home using the AM2+ device.", "populationDescription": "FAS including all patients who contributed data for this endpoint.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Percentage of asthma symptom free days", "timeFrame": "2-4 weeks", "groups": [{"id": "OG000", "title": "Placebo", "description": "Equivalent Placebo (morning and evening) delivered by the matching Inhaler (Respimat or Aerolizer)."}, {"id": "OG001", "title": "Olo 2 mcg qd", "description": "Olodaterol 2 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler."}, {"id": "OG002", "title": "Olo 5 mcg qd", "description": "Olodaterol 5 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler."}, {"id": "OG003", "title": "Olo 10 mcg qd", "description": "Olodaterol 10 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler."}, {"id": "OG004", "title": "Olo 20 mcg qd", "description": "Olodaterol 20 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler."}, {"id": "OG005", "title": "Form 12 mcg Bid", "description": "Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "123"}, {"groupId": "OG001", "value": "119"}, {"groupId": "OG002", "value": "126"}, {"groupId": "OG003", "value": "123"}, {"groupId": "OG004", "value": "120"}, {"groupId": "OG005", "value": "123"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "18.502", "spread": "2.494"}, {"groupId": "OG001", "value": "26.430", "spread": "2.973"}, {"groupId": "OG002", "value": "22.348", "spread": "2.835"}, {"groupId": "OG003", "value": "23.624", "spread": "2.951"}, {"groupId": "OG004", "value": "21.326", "spread": "2.803"}, {"groupId": "OG005", "value": "23.664", "spread": "2.797"}]}]}]}, {"type": "SECONDARY", "title": "Number of Patients Categorized by Highest Number of Night Time Awakenings (Overall)", "description": "Assessed by patients at home using the AM2+ device after the first 2 weeks of each period of randomised treatment.", "populationDescription": "FAS including all patients who contributed data for this endpoint.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Number of patients", "timeFrame": "2-4 weeks", "groups": [{"id": "OG000", "title": "Placebo", "description": "Equivalent Placebo (morning and evening) delivered by the matching Inhaler (Respimat or Aerolizer)."}, {"id": "OG001", "title": "Olo 2 mcg qd", "description": "Olodaterol 2 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler."}, {"id": "OG002", "title": "Olo 5 mcg qd", "description": "Olodaterol 5 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler."}, {"id": "OG003", "title": "Olo 10 mcg qd", "description": "Olodaterol 10 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler."}, {"id": "OG004", "title": "Olo 20 mcg qd", "description": "Olodaterol 20 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler."}, {"id": "OG005", "title": "Form 12 mcg Bid", "description": "Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "122"}, {"groupId": "OG001", "value": "119"}, {"groupId": "OG002", "value": "126"}, {"groupId": "OG003", "value": "123"}, {"groupId": "OG004", "value": "120"}, {"groupId": "OG005", "value": "123"}]}], "classes": [{"title": "Did not wake up", "categories": [{"measurements": [{"groupId": "OG000", "value": "55"}, {"groupId": "OG001", "value": "60"}, {"groupId": "OG002", "value": "58"}, {"groupId": "OG003", "value": "56"}, {"groupId": "OG004", "value": "63"}, {"groupId": "OG005", "value": "59"}]}]}, {"title": "Woke up once", "categories": [{"measurements": [{"groupId": "OG000", "value": "37"}, {"groupId": "OG001", "value": "36"}, {"groupId": "OG002", "value": "34"}, {"groupId": "OG003", "value": "34"}, {"groupId": "OG004", "value": "34"}, {"groupId": "OG005", "value": "29"}]}]}, {"title": "Woke up 2-5 times", "categories": [{"measurements": [{"groupId": "OG000", "value": "26"}, {"groupId": "OG001", "value": "17"}, {"groupId": "OG002", "value": "30"}, {"groupId": "OG003", "value": "30"}, {"groupId": "OG004", "value": "20"}, {"groupId": "OG005", "value": "33"}]}]}, {"title": "Woke up > 5 times", "categories": [{"measurements": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "5"}, {"groupId": "OG002", "value": "2"}, {"groupId": "OG003", "value": "1"}, {"groupId": "OG004", "value": "2"}, {"groupId": "OG005", "value": "2"}]}]}, {"title": "Was awake all night", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "2"}, {"groupId": "OG003", "value": "2"}, {"groupId": "OG004", "value": "1"}, {"groupId": "OG005", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Number of Patients Categorized by Worst Asthma Daytime Symptoms (Overall)", "description": "Assessed by patients at home using the AM2+ device after the first 2 weeks of each period of randomised treatment.", "populationDescription": "FAS including all patients who contributed data for this endpoint.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Number of patients", "timeFrame": "2-4 weeks", "groups": [{"id": "OG000", "title": "Placebo", "description": "Equivalent Placebo (morning and evening) delivered by the matching Inhaler (Respimat or Aerolizer)."}, {"id": "OG001", "title": "Olo 2 mcg qd", "description": "Olodaterol 2 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler."}, {"id": "OG002", "title": "Olo 5 mcg qd", "description": "Olodaterol 5 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler."}, {"id": "OG003", "title": "Olo 10 mcg qd", "description": "Olodaterol 10 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler."}, {"id": "OG004", "title": "Olo 20 mcg qd", "description": "Olodaterol 20 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler."}, {"id": "OG005", "title": "Form 12 mcg Bid", "description": "Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "122"}, {"groupId": "OG001", "value": "119"}, {"groupId": "OG002", "value": "126"}, {"groupId": "OG003", "value": "123"}, {"groupId": "OG004", "value": "120"}, {"groupId": "OG005", "value": "123"}]}], "classes": [{"title": "No asthma symptoms", "categories": [{"measurements": [{"groupId": "OG000", "value": "20"}, {"groupId": "OG001", "value": "26"}, {"groupId": "OG002", "value": "29"}, {"groupId": "OG003", "value": "23"}, {"groupId": "OG004", "value": "21"}, {"groupId": "OG005", "value": "24"}]}]}, {"title": "Mild asthma symptoms", "categories": [{"measurements": [{"groupId": "OG000", "value": "31"}, {"groupId": "OG001", "value": "46"}, {"groupId": "OG002", "value": "29"}, {"groupId": "OG003", "value": "37"}, {"groupId": "OG004", "value": "38"}, {"groupId": "OG005", "value": "37"}]}]}, {"title": "Moderate asthma symptoms", "categories": [{"measurements": [{"groupId": "OG000", "value": "56"}, {"groupId": "OG001", "value": "37"}, {"groupId": "OG002", "value": "51"}, {"groupId": "OG003", "value": "52"}, {"groupId": "OG004", "value": "54"}, {"groupId": "OG005", "value": "49"}]}]}, {"title": "Severe asthma symptoms", "categories": [{"measurements": [{"groupId": "OG000", "value": "15"}, {"groupId": "OG001", "value": "10"}, {"groupId": "OG002", "value": "12"}, {"groupId": "OG003", "value": "10"}, {"groupId": "OG004", "value": "6"}, {"groupId": "OG005", "value": "12"}]}]}, {"title": "Very severe asthma symptoms", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "5"}, {"groupId": "OG003", "value": "1"}, {"groupId": "OG004", "value": "1"}, {"groupId": "OG005", "value": "1"}]}]}]}, {"type": "SECONDARY", "title": "Number of Patients Categorized by Worst Asthma Nighttime Symptoms (Overall)", "description": "Assessed by patients at home using the AM2+ device after the first 2 weeks of each period of randomised treatment.", "populationDescription": "FAS including all patients who contributed data for this endpoint.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Number of patients", "timeFrame": "2-4 weeks", "groups": [{"id": "OG000", "title": "Placebo", "description": "Equivalent Placebo (morning and evening) delivered by the matching Inhaler (Respimat or Aerolizer)."}, {"id": "OG001", "title": "Olo 2 mcg qd", "description": "Olodaterol 2 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler."}, {"id": "OG002", "title": "Olo 5 mcg qd", "description": "Olodaterol 5 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler."}, {"id": "OG003", "title": "Olo 10 mcg qd", "description": "Olodaterol 10 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler."}, {"id": "OG004", "title": "Olo 20 mcg qd", "description": "Olodaterol 20 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler."}, {"id": "OG005", "title": "Form 12 mcg Bid", "description": "Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "122"}, {"groupId": "OG001", "value": "119"}, {"groupId": "OG002", "value": "126"}, {"groupId": "OG003", "value": "123"}, {"groupId": "OG004", "value": "120"}, {"groupId": "OG005", "value": "123"}]}], "classes": [{"title": "No asthma symptoms", "categories": [{"measurements": [{"groupId": "OG000", "value": "27"}, {"groupId": "OG001", "value": "31"}, {"groupId": "OG002", "value": "22"}, {"groupId": "OG003", "value": "25"}, {"groupId": "OG004", "value": "27"}, {"groupId": "OG005", "value": "26"}]}]}, {"title": "Mild asthma symptoms", "categories": [{"measurements": [{"groupId": "OG000", "value": "32"}, {"groupId": "OG001", "value": "47"}, {"groupId": "OG002", "value": "48"}, {"groupId": "OG003", "value": "40"}, {"groupId": "OG004", "value": "45"}, {"groupId": "OG005", "value": "39"}]}]}, {"title": "Moderate asthma symptoms", "categories": [{"measurements": [{"groupId": "OG000", "value": "49"}, {"groupId": "OG001", "value": "29"}, {"groupId": "OG002", "value": "45"}, {"groupId": "OG003", "value": "46"}, {"groupId": "OG004", "value": "43"}, {"groupId": "OG005", "value": "46"}]}]}, {"title": "Severe asthma symptoms", "categories": [{"measurements": [{"groupId": "OG000", "value": "14"}, {"groupId": "OG001", "value": "10"}, {"groupId": "OG002", "value": "11"}, {"groupId": "OG003", "value": "10"}, {"groupId": "OG004", "value": "5"}, {"groupId": "OG005", "value": "10"}]}]}, {"title": "Very severe asthma symptoms", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "2"}, {"groupId": "OG004", "value": "0"}, {"groupId": "OG005", "value": "2"}]}]}]}, {"type": "SECONDARY", "title": "Total Asthma Quality of Life Questionnaire (AQLQ(s)) Score", "description": "Total score from the Standardised Asthma Quality of Life Questionnaire (AQLQ (s)) at the end of each 4 week treatment period. The AQLQ(s) contains 32 questions, each question has a 7 point scale from 1 (highest intensity) till 7 (no symptoms). Total score was defined as the sum of all items divided by the number of items.", "populationDescription": "FAS including all patients who contributed data for this endpoint.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "units on a scale", "timeFrame": "4 weeks", "groups": [{"id": "OG000", "title": "Placebo", "description": "Equivalent Placebo (morning and evening) delivered by the matching Inhaler (Respimat or Aerolizer)."}, {"id": "OG001", "title": "Olo 2 mcg qd", "description": "Olodaterol 2 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler."}, {"id": "OG002", "title": "Olo 5 mcg qd", "description": "Olodaterol 5 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler."}, {"id": "OG003", "title": "Olo 10 mcg qd", "description": "Olodaterol 10 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler."}, {"id": "OG004", "title": "Olo 20 mcg qd", "description": "Olodaterol 20 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler."}, {"id": "OG005", "title": "Form 12 mcg Bid", "description": "Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "122"}, {"groupId": "OG001", "value": "119"}, {"groupId": "OG002", "value": "125"}, {"groupId": "OG003", "value": "121"}, {"groupId": "OG004", "value": "118"}, {"groupId": "OG005", "value": "122"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "5.174", "spread": "0.063"}, {"groupId": "OG001", "value": "5.463", "spread": "0.064"}, {"groupId": "OG002", "value": "5.383", "spread": "0.063"}, {"groupId": "OG003", "value": "5.437", "spread": "0.063"}, {"groupId": "OG004", "value": "5.491", "spread": "0.064"}, {"groupId": "OG005", "value": "5.489", "spread": "0.063"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Mean Difference (Final Values)", "paramValue": "0.289", "ciPctValue": "95", "ciLowerLimit": "0.178", "ciUpperLimit": "0.400", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.057", "estimateComment": "Olo 2 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0002", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Mean Difference (Final Values)", "paramValue": "0.209", "ciPctValue": "95", "ciLowerLimit": "0.099", "ciUpperLimit": "0.318", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.056", "estimateComment": "Olo 5 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Mean Difference (Final Values)", "paramValue": "0.262", "ciPctValue": "95", "ciLowerLimit": "0.151", "ciUpperLimit": "0.374", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.057", "estimateComment": "Olo 10 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG004"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Mean Difference (Final Values)", "paramValue": "0.317", "ciPctValue": "95", "ciLowerLimit": "0.205", "ciUpperLimit": "0.429", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.057", "estimateComment": "Olo 20 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG005"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Mean Difference (Final Values)", "paramValue": "0.315", "ciPctValue": "95", "ciLowerLimit": "0.203", "ciUpperLimit": "0.426", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.057", "estimateComment": "Form 12 mcg bid minus Placebo"}]}, {"type": "SECONDARY", "title": "Total Asthma Control Questionnaire (ACQ) Score", "description": "Control of asthma as assessed by the ACQ at the end of each 4-week treatment period.The ACQ contains 7 questions, each question has a 7 point scale from 0 (no symptoms) till 6 (highest intensity). Total score was defined as the sum of all items divided by the number of items.", "populationDescription": "FAS including all patients who contributed data for this endpoint.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "units on a scale", "timeFrame": "4 weeks", "groups": [{"id": "OG000", "title": "Placebo", "description": "Equivalent Placebo (morning and evening) delivered by the matching Inhaler (Respimat or Aerolizer)."}, {"id": "OG001", "title": "Olo 2 mcg qd", "description": "Olodaterol 2 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler."}, {"id": "OG002", "title": "Olo 5 mcg qd", "description": "Olodaterol 5 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler."}, {"id": "OG003", "title": "Olo 10 mcg qd", "description": "Olodaterol 10 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler."}, {"id": "OG004", "title": "Olo 20 mcg qd", "description": "Olodaterol 20 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler."}, {"id": "OG005", "title": "Form 12 mcg Bid", "description": "Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "123"}, {"groupId": "OG001", "value": "119"}, {"groupId": "OG002", "value": "126"}, {"groupId": "OG003", "value": "122"}, {"groupId": "OG004", "value": "119"}, {"groupId": "OG005", "value": "122"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.882", "spread": "0.058"}, {"groupId": "OG001", "value": "1.561", "spread": "0.058"}, {"groupId": "OG002", "value": "1.589", "spread": "0.057"}, {"groupId": "OG003", "value": "1.556", "spread": "0.058"}, {"groupId": "OG004", "value": "1.488", "spread": "0.058"}, {"groupId": "OG005", "value": "1.536", "spread": "0.058"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.321", "ciPctValue": "95", "ciLowerLimit": "-0.432", "ciUpperLimit": "-0.210", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.057", "estimateComment": "Olo 2 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.293", "ciPctValue": "95", "ciLowerLimit": "-0.403", "ciUpperLimit": "-0.184", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.056", "estimateComment": "Olo 5 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.326", "ciPctValue": "95", "ciLowerLimit": "-0.436", "ciUpperLimit": "-0.215", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.056", "estimateComment": "Olo 10 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG004"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.394", "ciPctValue": "95", "ciLowerLimit": "-0.505", "ciUpperLimit": "-0.282", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.057", "estimateComment": "Olo 20 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG005"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.346", "ciPctValue": "95", "ciLowerLimit": "-0.457", "ciUpperLimit": "-0.235", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.056", "estimateComment": "Form 12 mcg bid minus Placebo"}]}, {"type": "SECONDARY", "title": "Potassium 1 Hour Pre-dose", "description": "Effect on potassium evaluated 1 hour pre-dose. Analysis is based on the log of the potassium values. For the geometric means, the results were back-transformed to the original scale.", "populationDescription": "Treated set", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mmol/L", "timeFrame": "4 weeks", "groups": [{"id": "OG000", "title": "Placebo", "description": "Equivalent Placebo (morning and evening) delivered by the matching Inhaler (Respimat or Aerolizer)."}, {"id": "OG001", "title": "Olo 2 mcg qd", "description": "Olodaterol 2 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler."}, {"id": "OG002", "title": "Olo 5 mcg qd", "description": "Olodaterol 5 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler."}, {"id": "OG003", "title": "Olo 10 mcg qd", "description": "Olodaterol 10 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler."}, {"id": "OG004", "title": "Olo 20 mcg qd", "description": "Olodaterol 20 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler."}, {"id": "OG005", "title": "Form 12 mcg Bid", "description": "Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "119"}, {"groupId": "OG001", "value": "118"}, {"groupId": "OG002", "value": "122"}, {"groupId": "OG003", "value": "117"}, {"groupId": "OG004", "value": "117"}, {"groupId": "OG005", "value": "119"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "4.067", "lowerLimit": "4.019", "upperLimit": "4.114"}, {"groupId": "OG001", "value": "4.051", "lowerLimit": "4.004", "upperLimit": "4.099"}, {"groupId": "OG002", "value": "4.051", "lowerLimit": "4.005", "upperLimit": "4.097"}, {"groupId": "OG003", "value": "4.061", "lowerLimit": "4.014", "upperLimit": "4.109"}, {"groupId": "OG004", "value": "4.057", "lowerLimit": "4.010", "upperLimit": "4.105"}, {"groupId": "OG005", "value": "4.080", "lowerLimit": "4.032", "upperLimit": "4.128"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.6187", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Ratio of geometric means", "paramValue": "0.996", "ciPctValue": "95", "ciLowerLimit": "0.981", "ciUpperLimit": "1.011", "estimateComment": "Olo 2 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.6022", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Ratio of geometric means", "paramValue": "0.996", "ciPctValue": "95", "ciLowerLimit": "0.981", "ciUpperLimit": "1.011", "estimateComment": "Olo 5 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.8641", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Ratio of geometric means", "paramValue": "0.999", "ciPctValue": "95", "ciLowerLimit": "0.984", "ciUpperLimit": "1.014", "estimateComment": "Olo 10 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG004"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.7664", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Ratio of geometric means", "paramValue": "0.998", "ciPctValue": "95", "ciLowerLimit": "0.983", "ciUpperLimit": "1.013", "estimateComment": "Olo 20 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG005"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.6757", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Ratio of geometric means", "paramValue": "1.003", "ciPctValue": "95", "ciLowerLimit": "0.988", "ciUpperLimit": "1.018", "estimateComment": "Form 12 mcg bid minus Placebo"}]}, {"type": "SECONDARY", "title": "Potassium 1 Hour Post-dose", "description": "Effect on potassium evaluated 1 hour post-dose. Analysis is based on the log of the potassium values. For the geometric means, the results were back-transformed to the original scale.", "populationDescription": "Treated set", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mmol/L", "timeFrame": "4 weeks", "groups": [{"id": "OG000", "title": "Placebo", "description": "Equivalent Placebo (morning and evening) delivered by the matching Inhaler (Respimat or Aerolizer)."}, {"id": "OG001", "title": "Olo 2 mcg qd", "description": "Olodaterol 2 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler."}, {"id": "OG002", "title": "Olo 5 mcg qd", "description": "Olodaterol 5 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler."}, {"id": "OG003", "title": "Olo 10 mcg qd", "description": "Olodaterol 10 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler."}, {"id": "OG004", "title": "Olo 20 mcg qd", "description": "Olodaterol 20 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler."}, {"id": "OG005", "title": "Form 12 mcg Bid", "description": "Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "115"}, {"groupId": "OG001", "value": "113"}, {"groupId": "OG002", "value": "118"}, {"groupId": "OG003", "value": "114"}, {"groupId": "OG004", "value": "109"}, {"groupId": "OG005", "value": "114"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "4.097", "lowerLimit": "4.040", "upperLimit": "4.155"}, {"groupId": "OG001", "value": "4.069", "lowerLimit": "4.012", "upperLimit": "4.126"}, {"groupId": "OG002", "value": "4.013", "lowerLimit": "3.958", "upperLimit": "4.069"}, {"groupId": "OG003", "value": "4.004", "lowerLimit": "3.948", "upperLimit": "4.060"}, {"groupId": "OG004", "value": "4.015", "lowerLimit": "3.957", "upperLimit": "4.073"}, {"groupId": "OG005", "value": "4.059", "lowerLimit": "4.003", "upperLimit": "4.117"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.4423", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Ratio of geometric means", "paramValue": "0.993", "ciPctValue": "95", "ciLowerLimit": "0.975", "ciUpperLimit": "1.011", "estimateComment": "Olo 2 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0218", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Ratio of geometric means", "paramValue": "0.979", "ciPctValue": "95", "ciLowerLimit": "0.962", "ciUpperLimit": "0.997", "estimateComment": "Olo 5 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0109", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Ratio of geometric means", "paramValue": "0.977", "ciPctValue": "95", "ciLowerLimit": "0.960", "ciUpperLimit": "0.995", "estimateComment": "Olo 10 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG004"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0283", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Ratio of geometric means", "paramValue": "0.980", "ciPctValue": "95", "ciLowerLimit": "0.962", "ciUpperLimit": "0.998", "estimateComment": "Olo 20 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG005"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.3085", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Ratio of geometric means", "paramValue": "0.991", "ciPctValue": "95", "ciLowerLimit": "0.973", "ciUpperLimit": "1.009", "estimateComment": "Form 12 mcg bid minus Placebo"}]}, {"type": "SECONDARY", "title": "Potassium 3 Hours Post-dose", "description": "Effect on potassium evaluated 3 hours post-dose. Analysis is based on the log of the potassium values. For the geometric means, the results were back-transformed to the original scale.", "populationDescription": "Treated set", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mmol/L", "timeFrame": "4 weeks", "groups": [{"id": "OG000", "title": "Placebo", "description": "Equivalent Placebo (morning and evening) delivered by the matching Inhaler (Respimat or Aerolizer)."}, {"id": "OG001", "title": "Olo 2 mcg qd", "description": "Olodaterol 2 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler."}, {"id": "OG002", "title": "Olo 5 mcg qd", "description": "Olodaterol 5 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler."}, {"id": "OG003", "title": "Olo 10 mcg qd", "description": "Olodaterol 10 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler."}, {"id": "OG004", "title": "Olo 20 mcg qd", "description": "Olodaterol 20 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler."}, {"id": "OG005", "title": "Form 12 mcg Bid", "description": "Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "113"}, {"groupId": "OG001", "value": "110"}, {"groupId": "OG002", "value": "119"}, {"groupId": "OG003", "value": "114"}, {"groupId": "OG004", "value": "105"}, {"groupId": "OG005", "value": "114"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "4.029", "lowerLimit": "3.980", "upperLimit": "4.079"}, {"groupId": "OG001", "value": "4.026", "lowerLimit": "3.976", "upperLimit": "4.076"}, {"groupId": "OG002", "value": "3.997", "lowerLimit": "3.950", "upperLimit": "4.045"}, {"groupId": "OG003", "value": "3.979", "lowerLimit": "3.931", "upperLimit": "4.027"}, {"groupId": "OG004", "value": "3.992", "lowerLimit": "3.942", "upperLimit": "4.043"}, {"groupId": "OG005", "value": "4.007", "lowerLimit": "3.959", "upperLimit": "4.056"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.9112", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Ratio of geometric means", "paramValue": "0.999", "ciPctValue": "95", "ciLowerLimit": "0.984", "ciUpperLimit": "1.015", "estimateComment": "Olo 2 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.2955", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Ratio of geometric means", "paramValue": "0.992", "ciPctValue": "95", "ciLowerLimit": "0.977", "ciUpperLimit": "1.007", "estimateComment": "Olo 5 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.1029", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Ratio of geometric means", "paramValue": "0.987", "ciPctValue": "95", "ciLowerLimit": "0.973", "ciUpperLimit": "1.003", "estimateComment": "Olo 10 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG004"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.2552", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Ratio of geometric means", "paramValue": "0.991", "ciPctValue": "95", "ciLowerLimit": "0.975", "ciUpperLimit": "1.007", "estimateComment": "Olo 20 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG005"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.4803", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.", "paramType": "Ratio of geometric means", "paramValue": "0.994", "ciPctValue": "95", "ciLowerLimit": "0.979", "ciUpperLimit": "1.010", "estimateComment": "Form 12 mcg bid minus Placebo"}]}, {"type": "SECONDARY", "title": "Clinical Relevant Abnormalities for Vital Signs, Blood Chemistry, Haematology, Urinalysis and ECG", "description": "Clinical relevant abnormalities for Vital Signs, Blood Chemistry, Haematology, Urinalysis and ECG. New abnormal findings or worsening of baseline conditions were reported as Adverse Events.", "populationDescription": "Treated Set", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "4 weeks", "groups": [{"id": "OG000", "title": "Placebo", "description": "Equivalent Placebo (morning and evening) delivered by the matching Inhaler (Respimat or Aerolizer)."}, {"id": "OG001", "title": "Olo 2 mcg qd", "description": "Olodaterol 2 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler."}, {"id": "OG002", "title": "Olo 5 mcg qd", "description": "Olodaterol 5 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler."}, {"id": "OG003", "title": "Olo 10 mcg qd", "description": "Olodaterol 10 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler."}, {"id": "OG004", "title": "Olo 20 mcg qd", "description": "Olodaterol 20 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler."}, {"id": "OG005", "title": "Form 12 mcg Bid", "description": "Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "125"}, {"groupId": "OG001", "value": "121"}, {"groupId": "OG002", "value": "130"}, {"groupId": "OG003", "value": "127"}, {"groupId": "OG004", "value": "124"}, {"groupId": "OG005", "value": "125"}]}], "classes": [{"title": "Atrioventricular block first degree", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "1"}, {"groupId": "OG005", "value": "1"}]}]}, {"title": "Blood creatine phosphokinase MB increased", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "1"}, {"groupId": "OG004", "value": "0"}, {"groupId": "OG005", "value": "0"}]}]}, {"title": "Blood creatine phosphokinase increased", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "1"}, {"groupId": "OG004", "value": "0"}, {"groupId": "OG005", "value": "0"}]}]}, {"title": "Blood pressure increased", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "0"}, {"groupId": "OG005", "value": "0"}]}]}, {"title": "Hypothyroidism", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "1"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "0"}, {"groupId": "OG005", "value": "0"}]}]}, {"title": "Hypertension", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "1"}, {"groupId": "OG003", "value": "1"}, {"groupId": "OG004", "value": "1"}, {"groupId": "OG005", "value": "0"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "4 weeks", "eventGroups": [{"id": "EG000", "title": "Placebo", "description": "Equivalent Placebo (morning and evening) delivered by the matching Inhaler (Respimat or Aerolizer).", "seriousNumAffected": 0, "seriousNumAtRisk": 125, "otherNumAffected": 0, "otherNumAtRisk": 125}, {"id": "EG001", "title": "Olo 2 mcg", "description": "Olodaterol 2 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.", "seriousNumAffected": 0, "seriousNumAtRisk": 121, "otherNumAffected": 0, "otherNumAtRisk": 121}, {"id": "EG002", "title": "Olo 5 mcg", "description": "Olodaterol 5 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.", "seriousNumAffected": 0, "seriousNumAtRisk": 130, "otherNumAffected": 0, "otherNumAtRisk": 130}, {"id": "EG003", "title": "Olo 10 mcg", "description": "Olodaterol 10 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.", "seriousNumAffected": 1, "seriousNumAtRisk": 127, "otherNumAffected": 0, "otherNumAtRisk": 127}, {"id": "EG004", "title": "Olo 20 mcg", "description": "Olodaterol 20 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.", "seriousNumAffected": 0, "seriousNumAtRisk": 124, "otherNumAffected": 0, "otherNumAtRisk": 124}, {"id": "EG005", "title": "Form 12 mcg", "description": "Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler.", "seriousNumAffected": 0, "seriousNumAtRisk": 125, "otherNumAffected": 0, "otherNumAtRisk": 125}], "seriousEvents": [{"term": "Appendicitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 125}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 121}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 130}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 127}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 124}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 125}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication"}, "pointOfContact": {"title": "Boehringer Ingelheim Call Center", "organization": "Boehringer Ingelheim Pharmaceuticals", "email": "clintriage.rdg@boehringer-ingelheim.com", "phone": "1-800-243-0127"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M27137", "name": "Respiratory Aspiration", "relevance": "LOW"}, {"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC20", "name": "Immune System Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000068759", "term": "Formoterol Fumarate"}, {"id": "C000549647", "term": "Olodaterol"}], "ancestors": [{"id": "D000001993", "term": "Bronchodilator Agents"}, {"id": "D000001337", "term": "Autonomic Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}, {"id": "D000058666", "term": "Adrenergic beta-2 Receptor Agonists"}, {"id": "D000000318", "term": "Adrenergic beta-Agonists"}, {"id": "D000000322", "term": "Adrenergic Agonists"}, {"id": "D000018663", "term": "Adrenergic Agents"}, {"id": "D000018377", "term": "Neurotransmitter Agents"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M21860", "name": "Pharmaceutical Solutions", "relevance": "LOW"}, {"id": "M304", "name": "Formoterol Fumarate", "asFound": "Nicotine", "relevance": "HIGH"}, {"id": "M254406", "name": "Olodaterol", "asFound": "Preeclampsia", "relevance": "HIGH"}, {"id": "M5269", "name": "Bronchodilator Agents", "relevance": "LOW"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}, {"id": "M20746", "name": "Adrenergic Agents", "relevance": "LOW"}, {"id": "M3670", "name": "Adrenergic beta-Agonists", "relevance": "LOW"}, {"id": "M3673", "name": "Adrenergic Agonists", "relevance": "LOW"}, {"id": "M20504", "name": "Neurotransmitter Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "PhSol", "name": "Pharmaceutical Solutions"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}]}}, "hasResults": true}